Veeva Systems (VEEV) 10-K 30 Mar 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Jan. 31, 2022	Feb. 28, 2022	Jul. 31, 2021
Document And Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 31, 2022
Current Fiscal Year End Date	--01-31
Document Transition Report	false
Entity File Number	001-36121
Entity Registrant Name	Veeva Systems Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8235463
Entity Address, Address Line One	4280 Hacienda Drive
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	452-6500
Title of 12(b) Security	Class A Common Stock,par value $0.00001 per share
Trading Symbol	VEEV
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 46.2
Documents Incorporated by Reference	Portions of the Registrant’s Proxy Statement for the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Form 10-K to the extent stated herein. The proxy statement will be filed by the Registrant with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended January 31, 2022.
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Central Index Key	0001393052
Class A common stock
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		139,594,253
Class B common stock
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding (in shares)		14,764,740

Audit Information

Audit Information	12 Months Ended
	Jan. 31, 2022
Audit Information [Abstract]
Auditor Firm ID	185
Auditor Name	KPMG LLP
Auditor Location	Santa Clara, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,138,040	$ 730,504
Short-term investments	1,238,064	933,122
Accounts receivable, net of allowance for doubtful accounts of $473 and $193, respectively	631,134	564,387
Unbilled accounts receivable	63,266	47,206
Prepaid expenses and other current assets	36,679	35,607
Total current assets	3,107,183	2,310,826
Property and equipment, net	54,495	53,650
Deferred costs, net	33,106	42,072
Lease right-of-use assets	49,640	56,917
Goodwill	439,877	436,029
Intangible assets, net	101,940	114,595
Deferred income taxes	5,097	14,100
Other long-term assets	25,127	17,878
Total assets	3,816,465	3,046,067
Current liabilities:
Accounts payable	20,348	23,253
Accrued compensation and benefits	33,834	30,410
Accrued expenses and other current liabilities	36,109	30,982
Income tax payable	7,761	2,590
Deferred revenue	731,746	616,992
Lease liabilities	10,981	11,725
Total current liabilities	840,779	715,952
Deferred income taxes	2,216	1,835
Lease liabilities, noncurrent	43,607	51,393
Other long-term liabilities	18,226	10,567
Total liabilities	904,828	779,747
Commitments and contingencies (note 15)
Stockholders’ equity:
Additional paid-in capital	1,196,547	965,670
Accumulated other comprehensive (loss) income	(11,958)	992
Retained earnings	1,727,046	1,299,656
Total stockholders’ equity	2,911,637	2,266,320
Total liabilities and stockholders’ equity	3,816,465	3,046,067
Class A common stock
Stockholders’ equity:
Common stock	2	2
Class B common stock
Stockholders’ equity:
Common stock	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Allowance for doubtful accounts	$ 473	$ 193
Class A common stock
Common stock, par value (in usd per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	800,000,000	800,000,000
Common stock, shares issued (in shares)	139,432,822	137,062,817
Common stock, shares outstanding (in shares)	139,432,822	137,062,817
Class B common stock
Common stock, par value (in usd per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	190,000,000	190,000,000
Common stock, shares issued (in shares)	14,763,775	14,993,991
Common stock, shares outstanding (in shares)	14,763,775	14,993,991

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Revenues:
Total revenues		$ 1,850,777	$ 1,465,069	$ 1,104,081
Cost of revenues:
Total cost of revenues	[1]	503,678	408,928	303,369
Gross profit		1,347,099	1,056,141	800,712
Operating expenses:
Research and development	[1]	382,035	294,220	209,895
Sales and marketing	[1]	288,061	235,014	190,331
General and administrative	[1]	171,507	149,113	114,267
Total operating expenses	[1]	841,603	678,347	514,493
Operating income		505,496	377,794	286,219
Other income, net		6,815	16,199	27,478
Income before income taxes		512,311	393,993	313,697
Provision for income taxes		84,921	13,995	12,579
Net income		$ 427,390	$ 379,998	$ 301,118
Net income per share:
Basic (in usd per share)		$ 2.79	$ 2.52	$ 2.04
Diluted (in usd per share)		$ 2.63	$ 2.36	$ 1.90
Weighted-average shares used to compute net income per share:
Basic (in shares)		153,251	150,666	147,796
Diluted (in shares)		162,277	160,732	158,296
Other comprehensive income:
Net change in unrealized (loss) gain on available-for-sale investments, net of tax		$ (9,872)	$ 985	$ 2,388
Net change in cumulative foreign currency translation loss		(3,078)	(453)	(2,857)
Comprehensive income		414,440	380,530	300,649
Subscription services
Revenues:
Total revenues		1,483,976	1,179,486	896,294
Cost of revenues:
Total cost of revenues	[1]	224,911	184,589	136,328
Professional services and other
Revenues:
Total revenues		366,801	285,583	207,787
Cost of revenues:
Total cost of revenues	[1]	$ 278,767	$ 224,339	$ 167,041
[1]	(1) Includes stock-based compensation as follows: Cost of revenues: Cost of subscription services $ 4,795 $ 4,840 $ 2,638 Cost of professional services and other 36,293 27,698 17,518 Research and development 83,837 63,541 37,001 Sales and marketing 56,830 40,574 27,537 General and administrative 52,881 48,348 31,212 Total stock-based compensation $ 234,636 $ 185,001 $ 115,906

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Total stock-based compensation	$ 234,636	$ 185,001	$ 115,906
Cost of subscription services
Total stock-based compensation	4,795	4,840	2,638
Cost of professional services and other
Total stock-based compensation	36,293	27,698	17,518
Research and development
Total stock-based compensation	83,837	63,541	37,001
Sales and marketing
Total stock-based compensation	56,830	40,574	27,537
General and administrative
Total stock-based compensation	$ 52,881	$ 48,348	$ 31,212

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	[1]	Class A & B common stock	Additional paid-in capital	Retained earnings	Retained earningsCumulative Effect, Period of Adoption, Adjustment	[1]	Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Jan. 31, 2019				146,190,079
Beginning balance at Jan. 31, 2019	$ 1,237,749	$ (657)		$ 1	$ 617,623	$ 619,197	$ (657)		$ 928
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				1,665,778
Issuance of common stock upon    exercise of stock options	10,899				10,899
Issuance of common stock upon vesting of restricted stock units (in shares)				1,239,726
Replacement award value in connection with business combination	657
Stock-based compensation expense	116,296				116,296
Other comprehensive income (loss)	(468)								(468)
Net income	301,118					301,118
Ending balance (in shares) at Jan. 31, 2020				149,095,583
Ending balance at Jan. 31, 2020	1,665,594			$ 1	745,475	919,658			460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)				1,839,723
Issuance of common stock upon    exercise of stock options	34,816			$ 1	34,815
Issuance of common stock upon vesting of restricted stock units (in shares)				1,121,502
Stock-based compensation expense	185,380				185,380
Other comprehensive income (loss)	532								532
Net income	379,998					379,998
Ending balance (in shares) at Jan. 31, 2021				152,056,808
Ending balance at Jan. 31, 2021	$ 2,266,320			$ 2	965,670	1,299,656			992
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	1,476,898			1,476,898
Issuance of common stock upon    exercise of stock options	$ 51,538				51,538
Issuance of common stock upon vesting of restricted stock units (in shares)				854,536
Shares withheld related to net share settlement (in shares)	(191,645)
Shares withheld related to net share settlement	$ (56,398)
Stock-based compensation expense	235,737				235,737
Other comprehensive income (loss)	(12,950)								(12,950)
Net income	427,390					427,390
Ending balance (in shares) at Jan. 31, 2022				154,196,597
Ending balance at Jan. 31, 2022	$ 2,911,637			$ 2	$ 1,196,547	$ 1,727,046			$ (11,958)
[1]	(1) We adopted Accounting Standards Update (ASU) 2016-02, “ Leases ” (Topic 842) using the modified retrospective method as of February 1, 2019 and elected the transition option that allows us not to restate the comparative periods in our financial statements in the year of adoption.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Cash flows from operating activities
Net income	$ 427,390	$ 379,998	$ 301,118
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	27,448	29,455	19,859
Reduction of operating lease right-of-use assets	11,445	10,347	7,966
Amortization (accretion) of discount on short-term investments	6,264	3,134	(3,274)
Stock-based compensation	234,636	185,001	115,906
Amortization of deferred costs	26,050	20,677	20,521
Deferred income taxes	11,079	(1,048)	(6,663)
Gain on foreign currency from mark-to-market derivative	(782)	(365)	(120)
Bad debt expense (recovery)	272	(307)	244
Changes in operating assets and liabilities:
Accounts receivable	(67,020)	(174,067)	(55,531)
Unbilled accounts receivable	(16,060)	(14,387)	(14,555)
Deferred costs	(17,084)	(27,164)	(25,237)
Prepaid expenses and other current and long-term assets	(2,910)	(12,424)	(2,700)
Accounts payable	(2,997)	754	2,813
Accrued expenses and other current liabilities	9,439	13,889	(15,230)
Income taxes payable	5,275	(3,023)	1,131
Deferred revenue	116,144	147,479	97,753
Operating lease liabilities	(11,607)	(9,129)	(7,480)
Other long-term liabilities	7,481	2,426	854
Net cash provided by operating activities	764,463	551,246	437,375
Cash flows from investing activities
Purchases of short-term investments	(1,117,076)	(979,292)	(752,518)
Maturities and sales of short-term investments	792,918	654,341	688,091
Acquisitions, net of cash and restricted cash acquired	(7,780)	0	(448,162)
Long-term assets	(14,214)	(8,683)	(4,321)
Net cash used in investing activities	(346,152)	(333,634)	(516,910)
Cash flows from financing activities
Changes in lease liabilities - finance leases	(384)	(1,039)	(984)
Proceeds from exercise of common stock options	51,538	34,857	10,994
Taxes paid related to net share settlement of equity awards	(55,294)	0	0
Net cash (used in) provided by financing activities	(4,140)	33,818	10,010
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(4,657)	484	(2,856)
Net change in cash, cash equivalents, and restricted cash	409,514	251,914	(72,381)
Cash, cash equivalents, and restricted cash at beginning of period	731,711	479,797	552,178
Cash, cash equivalents, and restricted cash at end of period	1,141,225	731,711	479,797
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	1,138,040	730,504	476,733
Restricted cash included in other long-term assets	3,185	1,207	3,064
Cash, cash equivalents, and restricted cash at end of period	1,141,225	731,711	479,797
Supplemental disclosures of other cash flow information:
Cash paid for income taxes, net of refunds	58,627	18,096	14,289
Excess tax benefits from employee stock plans	56,172	80,661	50,411
Non-cash investing activities:
Changes in accounts payable and accrued expenses related to property and equipment purchases	$ (2,489)	$ 3,165	$ 567

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	12 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	Summary of Business and Significant Accounting Policies Description of Business Veeva is the leading provider of industry cloud solutions for the global life sciences industry. We were founded in 2007 on the premise that industry-specific cloud solutions could best address the operating challenges and regulatory requirements of life sciences companies. Our offerings span cloud software, data, analytics, professional services, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) to commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, quality, regulatory, and safety functions help life sciences companies streamline their end-to-end product development processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. We also bring the benefits of our content and data management solutions to a set of customers outside of life sciences in other regulated industries, including, for example, consumer goods, chemicals, and cosmetics. Our fiscal year end is January 31. Principles of Consolidation and Basis of Presentation These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding annual financial reporting and include the accounts of our wholly-owned subsidiaries after elimination of intercompany accounts and transactions. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to: • the standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations; • the determination of the period of benefit for amortization of deferred costs; • the realizability of deferred income tax assets and liabilities; • the fair value of our stock-based awards. As future events cannot be determined with precision, actual results could differ significantly from those estimates. Segment Information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. We define the term “chief operating decision maker” to be our Chief Executive Officer. Our Chief Executive Officer reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Since we operate in one operating segment, all required financial segment information can be found in the consolidated financial statements. Revenue Recognition We derive our revenues primarily from subscription services and professional services. Subscription services revenues consist of fees from customers accessing our cloud-based software solutions and fees for our data solutions. Professional services and other revenues consist primarily of fees from implementation services, configuration, data services, training, and managed services related to our solutions. Revenues are recognized when control of these services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. We determine revenue recognition through the following steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, we satisfy a performance obligation. Our subscription services agreements are generally non-cancelable during the term, although customers typically have the right to terminate their agreements for cause in the event of material breach. Subscription Services Revenues Subscription services revenues are recognized ratably over the respective non-cancelable subscription term because of the continuous transfer of control to the customer. Our subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Professional Services and Other Revenues The majority of our professional services arrangements are billed on a time and materials basis and revenues are recognized over time based on time incurred and contractually agreed upon rates. Certain professional services revenues are billed on a fixed fee basis and revenues are typically recognized over time as the services are delivered based on time incurred. Data services and training revenues are generally recognized as the services are performed. Contracts with Multiple Performance Obligations Some of our contracts with customers contain multiple performance obligations. For these contracts, we account for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions and other factors, including other groupings such as customer type and geography. Deferred Costs Deferred costs represents sales commissions associated with obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit that we have determined to be one Certain Risks and Concentrations of Credit Risk Our revenues are derived from subscription services, professional services and other services delivered primarily to the life sciences industry. We operate in markets that are highly competitive and rapidly changing. Significant technological changes, shifting customer needs, the emergence of competitive products or services with new capabilities, and other factors could negatively impact our future operating results. Our financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and trade accounts receivable. Our cash equivalents and short-term investments are held by established financial institutions. We have established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these financial institutions may significantly exceed federally insured limits. We do not require collateral from our customers and generally require payment within 30 days to 60 days of billing. The following customers individually exceeded 10% of total accounts receivable as of the dates shown: January 31, 2022 2021 Customer 1 10% 12% Customer 2 10% * * Does not exceed 10%. No single customer represented over 10% of our total revenues for any of the years presented. Cash Equivalents We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Short-term Investments Our short-term investments are classified as available-for-sale and recorded at estimated fair value. Unrealized gains and losses for available-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. We evaluate our investments to assess whether those with unrealized loss positions are other than temporarily impaired. We consider impairments to be other than temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other than temporary are determined based on the specific identification method and are reported in other income, net, in the consolidated statements of comprehensive income. Interest, amortization of premiums, and accretion of discount on all short-term investments are also included as a component of other income, net, in the consolidated statements of comprehensive income. We may sell our short-term investments at any time, without significant penalty, for use in current operations or for other purposes, even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond 12 months, as current assets in the accompanying consolidated balance sheets. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts, which is not material. Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets and commences once the asset is placed in service or ready for its intended use. Land is not depreciated. The estimated useful lives by asset classification are as follows: Building 30 years Land and building improvements 10 years (land improvements) and estimated useful life of building (building improvements) Equipment and computers 3 years Furniture and fixtures 5 years Leasehold improvements Shorter of remaining life of the lease term or estimated useful life Leases We have operating leases for corporate offices. Additionally, we are the sublessor for certain office space. We adopted Accounting Standards Update (ASU) 2016-02 “ Leases ” (Topic 842) using the modified retrospective method as of February 1, 2019 with an immaterial amount of cumulative effect adjustment recorded to our retained earnings. Subsequent to our adoption of Topic 842, we recognize lease right-of-use assets and liabilities at the commencement date based on the present value of lease payments over the lease term. We use an estimate of our discount rate based on the information available at the lease commencement date in determining the present value of lease payments, unless the implicit rate is readily determinable. The lease right-of-use assets also include any lease payments made and exclude lease incentives such as tenant improvement allowances. Options to extend or terminate the lease are included in the lease term when it is reasonably certain that we will exercise the extension or termination option. Our operating leases typically include non-lease components such as common-area maintenance costs. We have elected to exclude non-lease components from lease payments for the purpose of calculating lease right-of-use assets and liabilities and these are expensed as incurred as variable lease payments. Leases with a term of one year or less are not recognized on our consolidated balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Internal-Use Software We capitalize certain costs incurred for the development of computer software for internal use. We capitalize these costs during the development of the project, when it is determined that it is probable that the project will be completed and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training, and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life of three years, and the amortization expense is recorded as a component of cost of subscription services. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. Goodwill and Intangible Assets Goodwill is tested for impairment annually in the fourth quarter of each year or if circumstances indicate the carrying value of goodwill is impaired. We have one reporting unit and evaluate goodwill for impairment at the entity level. We completed our annual impairment test in our fourth quarter of the fiscal year ended January 31, 2022, which resulted in no impairment of the goodwill balance. All other intangible assets associated with purchased intangibles, consisting of existing technology, databases, customer relationships, software, trade names and trademarks, data supplier and partner relationships, non-competition agreements, brand, and backlog are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. Amortization expense related to existing technology, databases, data supplier and partner relationships, software, and backlog is included in cost of subscription services. Amortization expense related to customer relationships, trade names and trademarks, and brand are included in sales and marketing expense. Amortization expense related to non-competition agreements are included in both general and administrative and research and development expense. Long-Lived Assets Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented. Business Combinations The purchase price in a business combination is assigned to the estimated acquisition date fair values of the tangible and intangible assets acquired and the liabilities assumed with the residual recorded as goodwill. Critical estimates in valuing certain of the intangible assets include, but are not limited to, the net present value of future expected cash flows, future revenue growth, margins, customer retention rates, technology life, royalty rates, expected use of acquired assets, and discount rates. Stock-based Compensation We recognize compensation expense for all stock-based awards, including stock options and restricted stock units (RSUs), based on the estimate of fair value of the award at the grant date. The fair value of each option award is estimated on the grant date using either a Black-Scholes option-pricing model or a Monte Carlo simulation, to the extent market conditions exist, and a single option award approach. These models require that at the date of grant we determine the fair value of the underlying common stock, the expected term of the award, the expected volatility of the price of our common stock, risk-free interest rates, and expected dividend yield of our common stock. The fair value of each RSU award is measured based on the closing stock price of our common stock on the date of grant. We account for forfeitures as they occur. The compensation expense is recognized using a straight-line basis over the requisite service periods of the awards, which is one four Cost of Revenues Cost of subscription services revenues consists of expenses related to our computing infrastructure provided by third parties, including salesforce.com and Amazon Web Services, personnel-related costs associated with hosting our subscription services and providing support including our data stewards, data acquisition costs, and allocated overhead, amortization expense associated with capitalized internal-use software related to our subscription services, and amortization expense associated with purchased intangibles related to our subscription services. Cost of subscription services revenues for Veeva CRM and certain of our multichannel customer relationship management applications include fees paid to salesforce.com for our use of the Salesforce Platform and the associated hosting infrastructure and data center operations that are provided by salesforce.com. Cost of professional services and other revenues consists primarily of employee-related expenses associated with providing these services, including salaries, benefits and stock-based compensation expense, the cost of third-party subcontractors, travel costs, and allocated overhead. Advertising Expenses Advertising expenditures are expensed as incurred and were immaterial for each of the years presented. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We regularly assess the realizability of our deferred tax assets and establish a valuation allowance if it is more likely than not that some or all of our deferred tax assets will not be realized. We evaluate and weigh all available positive and negative evidence such as historic results, future reversals of existing deferred tax liabilities, projected future taxable income, as well as prudent and feasible tax-planning strategies. Generally, more weight is given to objectively verifiable evidence such as the cumulative income in recent years. We establish liabilities or reduce assets for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining whether the weight of available evidence indicates that it is more likely than not that the position will be sustained upon an audit, including resolution of related appeals or litigation processes, if any. The second step requires us to measure the tax benefit as the largest amount that is more likely than not to be realized upon ultimate settlement. We recognize interest accrued and penalties related to unrecognized tax benefits as a component of provision for income taxes. Foreign Currency Exchange Adjustments resulting from translating financial statements for those entities that do not have U.S. dollars as their functional currency are recorded as part of a separate component of the consolidated statements of comprehensive income. All assets and liabilities denominated in currencies other than U.S. dollars are translated into the U.S. dollar functional currency at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average exchange rate during the period. Equity transactions are translated using historical exchange rates. Foreign currency transaction gains and losses are included in the consolidated statements of comprehensive income for the period. Indemnification Our contracts generally include provisions for indemnifying customers against liabilities if our solutions infringe a third party’s intellectual property rights, and we may also incur liabilities if we breach the security and/or confidentiality obligations in our contracts. To date, we have not incurred any material costs, and we have not accrued any liabilities in the accompanying consolidated financial statements as a result of these obligations. Loss Contingencies Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. New Accounting Pronouncements Adopted in Fiscal 2022 Income Taxes In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ” which simplifies accounting guidance for certain tax matters. We adopted this standard effective February 1, 2021. The adoption of this new standard did not have a material impact on our consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Jan. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions Crossix On November 1, 2019, we acquired 100% ownership of Crossix in exchange for total consideration of $428 million, which includes the impact of adjustments to purchase price associated with the cash and net working capital of the acquired entity at close. In addition, we granted certain Crossix employees equity retention awards valued at approximately $120 million in the aggregate, which will be expensed as share-based compensation over the remaining service period. Crossix brings Veeva additional depth in patient data and data analytics. Crossix’s existing data analytics offerings are complementary to our existing Commercial Cloud offerings, and we are using the Crossix Data Platform to build our Veeva Data Cloud offerings. The following table summarizes the estimated fair values of the assets acquired, useful lives, and liabilities assumed at the acquisition date (in thousands): Useful life Fair value Net assets acquired $ 4,766 Identifiable intangible assets: Customer relationships 10 years 70,100 Existing technology 6 years 19,200 Trade name and trademarks 5 years 13,200 Other intangibles 1 to 7 years 6,000 Total purchased intangible assets 108,500 Goodwill 314,642 Total purchase consideration $ 427,908 The following unaudited pro forma information presents the combined results of operations for the periods presented as if the acquisition had been completed on February 1, 2019, the beginning of the comparable prior annual reporting period. The unaudited pro forma results include the amortization associated with estimates for the purchased intangible assets and stock-based compensation expense associated with the retention awards granted. The unaudited pro forma results do not reflect any cost saving synergies from operating efficiencies or the effect of the incremental costs incurred in integrating the two companies. Accordingly, these unaudited pro forma results are presented for information purpose only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations (in thousands): Fiscal Year Ended January 31, 2020 Pro forma revenues $ 1,153,497 Pro forma net income $ 278,215 Pro forma net income per share: Basic $ 1.88 Diluted $ 1.76 Physicians World On November 7, 2019, we completed our acquisition of Physicians World in exchange for total cash consideration of $41 million, which includes the impact of adjustments to purchase price associated with the cash and net working capital of the acquired entity at close. In addition, we granted certain Physicians World employees equity retention awards valued at approximately $15 million in the aggregate. The acquisition of Physicians World makes it easier for our customers to get industry leading cloud software and services from a single vendor. The legacy Physicians World business is now part of our Veeva Digital Events offerings. Pro forma results of operations have not been presented because the effect of this acquisition was not material to our consolidated financial statements. The following table summarizes the estimated fair values of the assets acquired, useful lives, and liabilities assumed at the acquisition date (in thousands): Useful life Fair value Net assets acquired $ 1,221 Identifiable intangible assets: Customer relationships 10 years $7,700 Existing technology 6 years 3,300 Trade name and trademarks 5 years 700 Total purchased intangible assets 11,700 Goodwill 28,083 Total purchase consideration $ 41,004

Short-Term Investments

Short-Term Investments	12 Months Ended
	Jan. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Short-Term Investments	Short-Term Investments At January 31, 2022, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 13,500 $ — $ (15) $ 13,485 Asset-backed securities 191,676 45 (1,432) 190,289 Commercial paper 29,432 — (2) 29,430 Corporate notes and bonds 669,489 276 (5,856) 663,909 Foreign government bonds 24,577 13 (179) 24,411 U.S. agency obligations 27,978 12 (254) 27,736 U.S. treasury securities 290,513 46 (1,755) 288,804 Total available-for-sale securities $ 1,247,165 $ 392 $ (9,493) $ 1,238,064 At January 31, 2021, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 17,350 $ 15 $ (1) $ 17,364 Asset-backed securities 125,833 745 (2) 126,576 Commercial paper 57,390 8 (2) 57,396 Corporate notes and bonds 428,710 2,360 (23) 431,047 Foreign government bonds 31,855 45 (2) 31,898 U.S. agency obligations 52,756 119 — 52,875 U.S. treasury securities 215,379 587 — 215,966 Total available-for-sale securities $ 929,273 $ 3,879 $ (30) $ 933,122 The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates shown (in thousands): January 31, 2022 2021 Due in one year or less $ 457,948 $ 428,155 Due in greater than one year 780,116 504,967 Total short-term investments $ 1,238,064 $ 933,122 We have not recorded an allowance for credit losses, as we believe any such losses would be immaterial based on the high credit quality of our investments. We intend to hold our securities to maturity and it is more likely than not we will hold these securities until recovery of the cost basis. The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2022 (in thousands): Held for less than 12 months Fair value Gross unrealized losses Certificates of deposits $ 5,985 $ (15) Asset-backed securities 177,056 (1,432) Commercial paper 17,190 (2) Corporate notes and bonds 571,099 (5,856) Foreign government bonds 19,594 (179) U.S. agency obligations 24,725 (254) U.S. treasury securities 247,509 (1,756) The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2021 (in thousands): Held for less than 12 months Fair value Gross unrealized losses Certificates of deposits $ 3,749 $ (2) Asset-backed securities 3,318 (1) Commercial paper 17,626 (2) Corporate notes and bonds 29,558 (23) Foreign government bonds 2,679 (2) Asset values and gross unrealized losses of available-for-sale securities held for more than 12 months as of January 31, 2022 and 2021 were immaterial. There were no impairments considered other-than-temporary as of January 31, 2022 and 2021 as it is more likely than not we will hold these securities until recovery of the cost basis.

Deferred Costs

Deferred Costs	12 Months Ended
	Jan. 31, 2022
Deferred Costs [Abstract]
Deferred Costs	Deferred CostsDeferred costs, which consists of deferred sales commissions, were $33 million and $42 million as of January 31, 2022 and January 31, 2021, respectively. Amortization expense for the deferred costs included in sales and marketing expenses in the consolidated statements of comprehensive income was $26 million, $21 million, and $21 million for the fiscal years ended January 31, 2022, 2021, and 2020, respectively. There have been no impairment losses recorded in relation to the costs capitalized for any period presented.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Jan. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net consists of the following as of the dates shown (in thousands): January 31, 2022 2021 Land $ 3,040 $ 3,040 Building 20,984 20,984 Land improvements and building improvements 22,392 22,392 Equipment and computers 3,581 8,847 Furniture and fixtures 15,040 13,452 Leasehold improvements 19,002 13,945 Construction in progress 730 606 84,769 83,266 Less accumulated depreciation (30,274) (29,616) Total property and equipment, net $ 54,495 $ 53,650

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Jan. 31, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill was $440 million and $436 million as of January 31, 2022 and January 31, 2021, respectively. The following schedule presents the details of goodwill as of January 31, 2022 (dollar amounts in thousands): Balance as of January 31, 2020 $ 438,529 Purchase price goodwill reduction from Crossix tax adjustments (2,500) Balance as of January 31, 2021 436,029 Goodwill from business acquisitions $ 3,848 Balance as of January 31, 2022 $ 439,877 The following schedule presents the details of intangible assets as of January 31, 2022 (dollar amounts in thousands): January 31, 2022 Gross carrying amount Accumulated amortization Net Remaining useful life (in years) Existing technology $ 28,580 $ (12,187) $ 16,393 3.9 Customer relationships 113,157 (38,829) 74,328 7.0 Trade name and trademarks 13,900 (6,645) 7,255 2.8 Other intangibles 21,405 (17,441) 3,964 3.8 Total intangible assets $ 177,042 $ (75,102) $ 101,940 The following schedule presents the details of intangible assets as of January 31, 2021 (dollar amounts in thousands): January 31, 2021 Gross Accumulated Net Remaining Existing technology $ 26,180 $ (8,367) $ 17,813 4.8 Customer relationships 110,643 (27,741) 82,902 8.0 Trade name and trademarks 13,900 (4,005) 9,895 3.8 Other intangibles 20,453 (16,468) 3,985 5.1 Total intangible assets $ 171,176 $ (56,581) $ 114,595 As of January 31, 2022, the estimated amortization expense for intangible assets, for the next five years and thereafter is as follows (in thousands): Fiscal 2023 $ 19,463 Fiscal 2024 19,459 Fiscal 2025 18,557 Fiscal 2026 14,147 Fiscal 2027 8,922 Thereafter 21,392 Total $ 101,940

Accrued Expenses

Accrued Expenses	12 Months Ended
	Jan. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consisted of the following as of the dates shown (in thousands): January 31, 2022 2021 Accrued commissions $ 8,556 $ 7,498 Accrued bonus 4,677 4,134 Accrued vacation 5,546 4,716 Payroll tax payable 9,487 10,250 Accrued other compensation and benefits 5,568 3,812 Total accrued compensation and benefits $ 33,834 $ 30,410 Accrued fees payable to salesforce.com $ 6,521 $ 6,381 Taxes payable 9,743 13,598 Accrued third-party professional services subcontractors' fees 1,961 1,515 Other accrued expenses 17,884 9,488 Total accrued expenses and other current liabilities $ 36,109 $ 30,982

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jan. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of accounts receivable and other current assets, accounts payable, and accrued liabilities approximate their fair value due to their short-term nature. Financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires management to make judgments and considers factors specific to the asset or liability. The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of January 31, 2022 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 428,411 $ — $ 428,411 Corporate notes and bonds — 5,853 5,853 Asset-backed securities — 2,568 2,568 Short-term investments: Certificates of deposits — 13,485 13,485 Asset-backed securities — 190,289 190,289 Commercial paper — 29,430 29,430 Corporate notes and bonds — 663,909 663,909 Foreign government bonds — 24,411 24,411 U.S. agency obligations — 27,736 27,736 U.S. Treasury securities — 288,804 288,804 Foreign currency derivative contracts — 1,222 1,222 Total financial assets $ 428,411 $ 1,247,707 $ 1,676,118 The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2021 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 259,937 $ — $ 259,937 U.S. Treasury securities — 15,520 15,520 Short-term investments: Certificates of deposits — 17,364 17,364 Asset-backed securities — 126,576 126,576 Commercial paper — 57,396 57,396 Corporate notes and bonds — 431,047 431,047 Foreign government bonds — 31,898 31,898 U.S. agency obligations — 52,875 52,875 U.S. Treasury securities — 215,966 215,966 Foreign currency derivative contracts — 440 440 Total financial assets $ 259,937 $ 949,082 $ 1,209,019 Liabilities Foreign currency derivative contracts $ — $ 72 $ 72 Total financial liabilities $ — $ 72 $ 72 We determine the fair value of our security holdings based on pricing from our service providers and market prices from industry-standard independent data providers. The valuation techniques used to measure the fair value of financial instruments having Level 2 inputs were derived from non-binding consensus prices that are corroborated by observable market data or quoted market prices for similar instruments. Such market prices may be quoted prices in active markets for identical assets (Level 1 inputs) or pricing determined using inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs). Balance Sheet Hedges We enter into foreign currency forward contracts in order to hedge our foreign currency exposure. We account for derivative instruments at fair value with changes in the fair value recorded as a component of other income, net, in our consolidated statements of comprehensive income. Cash flows from such forward contracts are classified as operating activities. The realized foreign currency gains and losses were not material for any of the fiscal years ended January 31, 2022, 2021, and 2020. The fair value of our outstanding derivative instruments is summarized below (in thousands): January 31, 2022 2021 Notional amount of foreign currency derivative contracts $ 87,097 $ 52,516 Fair value of foreign currency derivative contracts 85,876 52,148 Derivatives not designated as hedging instruments are presented as components of the following balance sheet items for the periods shown as follows (in thousands): January 31, Balance sheet presentation 2022 2021 Foreign currency derivative contracts - assets Prepaid expenses and other current assets $ 1,222 $ 440 Foreign currency derivative contracts - liabilities Accrued expenses — 72

Income Taxes

Income Taxes	12 Months Ended
	Jan. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The components of income before income taxes by U.S. and foreign jurisdictions were as follows for the periods shown (in thousands): Fiscal year ended January 31, 2022 2021 2020 United States $ 487,962 $ 378,042 $ 305,339 Foreign 24,349 15,951 8,358 Total $ 512,311 $ 393,993 $ 313,697 The majority of our revenues from international sales are invoiced from and collected by our U.S. entity and recognized as a component of income before taxes in the United States as opposed to a foreign jurisdiction. Provision for income taxes consisted of the following for the periods shown (in thousands): Fiscal year ended January 31, 2022 2021 2020 Current provision: Federal $ 53,426 $ 7,108 $ 11,143 State 12,580 4,763 4,695 Foreign 7,837 2,825 3,404 Total current provision 73,843 14,696 19,242 Deferred provision: Federal 1,870 (816) (1,063) State 945 681 (517) Foreign 8,264 (566) (5,083) Total deferred provision 11,079 (701) (6,663) Provision for income taxes $ 84,921 $ 13,995 $ 12,579 Provision for income taxes differed from the amount computed by applying the federal statutory income tax rate of 21% for each of the fiscal years ended January 31, 2022, 2021, and 2020 to income before income taxes as a result of the following for the periods shown (in thousands): Fiscal year ended January 31, 2022 2021 2020 Federal tax statutory tax rate $ 107,585 $ 82,739 $ 65,876 State taxes 11,035 4,401 3,035 Tax credits (25,968) (24,617) (23,468) Stock-based compensation (29,715) (54,488) (34,569) Valuation allowance 19,402 10,269 7,408 Foreign derived intangible income deduction (FDII) (3,406) (5,134) (4,836) Other (1) 5,988 825 (867) Provision for income taxes $ 84,921 $ 13,995 $ 12,579 (1) Prior period balances were adjusted to conform with current period presentation. The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and liabilities related to the following (in thousands): January 31, 2022 2021 Deferred tax assets: Accruals and reserves $ 7,068 $ 13,494 Capitalized expenditures 10,477 — Stock-based compensation 16,615 11,486 Net operating loss carryforward 21,850 29,318 Tax credit carryforward 34,725 29,624 Lease liabilities 13,813 15,932 Other (1) 2,955 977 Gross deferred tax assets 107,503 100,831 Valuation allowance (48,484) (31,318) Total deferred tax assets 59,019 69,513 Deferred tax liabilities: Intangible assets (31,200) (30,253) Lease right-of-use assets (12,497) (14,438) Deferred costs (1) (10,552) (11,481) Other (1) (1,889) (1,076) Total deferred tax liabilities (56,138) (57,248) Net deferred tax assets $ 2,881 $ 12,265 (1) Prior period balances were adjusted to conform with current period presentation. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The valuation allowance at the end of January 31, 2022 was primarily related to certain foreign and U.S. state deferred tax assets. As of January 31, 2022, the net operating loss carryforwards for federal, state, and foreign income tax purposes were approximately $48 million, $69 million, and $31 million, respectively. The federal net operating losses do not expire, while the state and foreign net operating losses begin to expire in 2031 and 2026, respectively. As of January 31, 2022, we had $54 million of California research and development tax credits available to offset future taxes which do not expire. We evaluate tax positions for recognition using a more likely than not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. We classify unrecognized tax benefits that are not expected to result in payment or receipt of cash within one year as “other non-current liabilities” in the consolidated balance sheets. As of January 31, 2022, the total amount of gross unrecognized tax benefits was $25 million, of which $14 million, if recognized, would favorably impact our effective tax rate. The aggregate changes in our total gross amount of unrecognized tax benefits are summarized as follows for the periods shown (in thousands): Fiscal year ended January 31, 2022 2021 2020 Beginning balance $ 18,628 $ 14,515 $ 12,597 Increases related to tax positions taken during the prior period 3,218 96 796 Increases related to tax positions taken during the current period 4,122 4,126 3,420 Decreases related to tax positions taken during the prior period — (51) (128) Audit settlements (195) — — Lapse of statute of limitations (532) (58) (2,170) Ending balance $ 25,241 $ 18,628 $ 14,515 Our policy is to classify interest and penalties associated with unrecognized tax benefits as a component of the provision for income taxes. Interest and penalties were not significant during fiscal year ended January 31, 2022. We file tax returns in the United States for federal, California, and other states. Fiscal years ended January 31, 2017 and forward remain open to examination for federal income tax, and fiscal years ended January 31, 2018 and forward remain open to examination for California and other states. We file tax returns in multiple foreign jurisdictions. The fiscal years ended January 31, 2017 and forward remain open to examination in these foreign jurisdictions.

Deferred Revenue, Performance O

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable	12 Months Ended
	Jan. 31, 2022
Revenue Recognition and Deferred Revenue [Abstract]
Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable	Deferred Revenue, Performance Obligations, and Unbilled Accounts ReceivableFrom the deferred revenue balance at the beginning of the respective periods, we recognized $605 million, $464 million, and $353 million of subscription services revenue during the fiscal years ended January 31, 2022, 2021, and 2020, respectively. Professional services revenue recognized in the same periods from the deferred revenue balances at the beginning of the respective periods was immaterial. Transaction Price Allocated to the Remaining Performance Obligations Transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. We applied the practical expedient in accordance with ASU 2014-09, “ Revenue from Contracts with Customers ” (Topic 606) to exclude the amounts related to professional services contracts as these contracts generally have a remaining duration of one year or less. As of January 31, 2022, approximately $1,507 million of revenue is expected to be recognized from remaining performance obligations for subscription services contracts. We expect to recognize revenue on approximately 79% of these remaining performance obligations over the next 12 months, with the balance recognized thereafter. Unbilled Accounts Receivable Unbilled accounts receivable consists of (i) a receivable primarily for the revenue recognized for professional services performed but not yet billed, which was $28 million and $20 million as of January 31, 2022 and January 31, 2021, respectively, and (ii) a contract asset primarily for revenue recognized from non-cancelable, multi-year orders in which fees increase annually but for which we are not contractually able to invoice until a future period, which was $36 million and $27 million as of January 31, 2022 and January 31, 2021, respectively.

Leases

Leases	12 Months Ended
	Jan. 31, 2022
Leases [Abstract]
Leases	Leases We have operating leases for corporate offices. Our leases have various expiration dates through 2030, some of which include options to extend the leases for up to nine years. Additionally, we are the sublessor for certain office space. Our sublease income for the fiscal years ended January 31, 2022 and 2021 was immaterial. For the fiscal years ended January 31, 2022, 2021, and 2020, our operating lease expense was $14 million, $13 million, and $8 million, respectively. Supplemental cash flow information related to leases was as follows (in thousands): Fiscal year ended January 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities $ 13,800 $ 11,401 Right-of-use assets obtained in exchange for lease obligations: Operating leases 3,848 12,214 Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate): January 31, 2022 2021 Lease right-of-use assets $ 49,640 $ 56,917 Lease liabilities $ 10,981 $ 11,347 Lease liabilities, noncurrent 43,607 51,393 Total operating lease liabilities $ 54,588 $ 62,740 Weighted Average Remaining Lease Term 6.0 years 6.7 years Weighted Average Discount Rate 3.7 % 3.8 % As of January 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal 2023 $ 12,143 Fiscal 2024 11,942 Fiscal 2025 8,951 Fiscal 2026 7,251 Fiscal 2027 6,316 Thereafter 14,674 Total operating lease payments 61,277 Less imputed interest 6,689 Total operating lease liabilities $ 54,588
Leases	Leases We have operating leases for corporate offices. Our leases have various expiration dates through 2030, some of which include options to extend the leases for up to nine years. Additionally, we are the sublessor for certain office space. Our sublease income for the fiscal years ended January 31, 2022 and 2021 was immaterial. For the fiscal years ended January 31, 2022, 2021, and 2020, our operating lease expense was $14 million, $13 million, and $8 million, respectively. Supplemental cash flow information related to leases was as follows (in thousands): Fiscal year ended January 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities $ 13,800 $ 11,401 Right-of-use assets obtained in exchange for lease obligations: Operating leases 3,848 12,214 Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate): January 31, 2022 2021 Lease right-of-use assets $ 49,640 $ 56,917 Lease liabilities $ 10,981 $ 11,347 Lease liabilities, noncurrent 43,607 51,393 Total operating lease liabilities $ 54,588 $ 62,740 Weighted Average Remaining Lease Term 6.0 years 6.7 years Weighted Average Discount Rate 3.7 % 3.8 % As of January 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal 2023 $ 12,143 Fiscal 2024 11,942 Fiscal 2025 8,951 Fiscal 2026 7,251 Fiscal 2027 6,316 Thereafter 14,674 Total operating lease payments 61,277 Less imputed interest 6,689 Total operating lease liabilities $ 54,588

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jan. 31, 2022
Share-based Payment Arrangement [Abstract]
Stockholders' Equity	Stockholders’ Equity Common Stock In connection with our initial public offering in October 2013 (IPO), we amended our certificate of incorporation to provide for Class A common stock, Class B common stock, and preferred stock. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock and common stock were converted into shares of Class B common stock. As a result, following the IPO, we have two classes of authorized common stock: Class A common stock and Class B common stock. As of January 31, 2022, we had 139,432,822 shares of Class A common stock and 14,763,775 shares of Class B common stock outstanding. As of January 31, 2021, we had 137,062,817 shares of Class A common stock and 14,993,991 shares of Class B common stock outstanding. Voting Rights The holders of our Class B common stock are entitled to ten votes per share, and holders of our Class A common stock are entitled to one vote per share. The holders of our Class A common stock and Class B common stock vote together as a single class, unless otherwise required by our restated certificate of incorporation or by law. Delaware law could require either holders of our Class A common stock or our Class B common stock to vote separately as a single class in the following circumstances: • if we were to seek to amend our restated certificate of incorporation to increase the authorized number of shares of a class of stock, or to increase or decrease the par value of a class of stock, then that class would be required to vote separately to approve the proposed amendment; and • if we were to seek to amend our restated certificate of incorporation in a manner that alters or changes the powers, preferences, or special rights of a class of stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment. Our restated certificate of incorporation requires the approval of a majority of our outstanding Class B common stock voting as a separate class for any transaction that would result in a change in control of our company. Dividend Rights Holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine. To date, no dividends have been declared or paid by us. No Preemptive or Similar Rights Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption, or sinking fund provisions. Right to Receive Liquidation Distributions Upon our dissolution, liquidation, or winding-up, the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock. Conversion Rights Each outstanding share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. In addition, each share of Class B common stock will convert automatically into one share of Class A common stock upon any transfer, whether or not for value, which occurs following the closing of our IPO, except for certain permitted transfers described in our restated certificate of incorporation, including transfers to any “permitted transferee” as defined in our restated certificate of incorporation, which includes, among others, transfers: • to trusts, corporations, limited liability companies, partnerships, foundations or similar entities established by a Class B stockholder, provided that: • such transfer is to entities established by a Class B stockholder where the Class B stockholder retains the exclusive right to vote and direct the disposition of the shares of Class B common stock; or • such transfer does not involve payment of cash, securities, property, or other consideration to the Class B stockholder. Once converted into Class A common stock, a share of Class B common stock may not be reissued. All the outstanding shares of Class A and Class B common stock will convert automatically into shares of a single class of common stock upon the earliest to occur of the following: (i) upon the election of the holders of a majority of the then-outstanding shares of Class B common stock or (ii) October 15, 2023. Following such conversion, each share of common stock will have one vote per share and the rights of the holders of all outstanding common stock will be identical. Once converted into a single class of common stock, the Class A and Class B common stock may not be reissued. Employee Equity Plans Beginning in the fiscal quarter ended April 30, 2019, we implemented a new equity compensation program applicable to the vast majority of our employees but not applicable to our Chief Executive Officer (CEO). Prior to the adoption of the new equity compensation program, at the time of hire, our employees received a grant of RSUs that vested quarterly over 4 years and received additional equity from time to time thereafter. Under the new equity compensation program, the vast majority of our employees are granted both RSUs, which typically vest over a one-year period, and stock options, which typically vest over a four-year period. 2007 Stock Plan Our board of directors adopted our 2007 Stock Plan (2007 Plan) in February 2007, and our stockholders approved it in February 2007. No further awards have been made under our 2007 Plan since the adoption of the 2012 Equity Incentive Plan. However, awards outstanding under our 2007 Plan will continue to be governed by their existing terms. 2012 Equity Incentive Plan Our board of directors adopted our 2012 Equity Incentive Plan (2012 EIP) in November 2012, and our stockholders approved it in December 2012. An amendment and restatement of the 2012 EIP was approved by our board of directors in March 2013, and our stockholders approved it in March 2013. The 2012 EIP became effective on adoption and replaced our 2007 Plan. No further awards have been made under our 2012 EIP since the adoption of the 2013 Equity Incentive Plan. However, awards outstanding under the 2012 EIP will continue to be governed by their existing terms. 2013 Equity Incentive Plan Our board of directors adopted our 2013 Equity Incentive Plan (2013 EIP) in August 2013, and our stockholders approved it in September 2013. The 2013 EIP became effective immediately on adoption although no awards were made under it until the date of our IPO on October 15, 2013, at which time our 2013 EIP replaced our 2012 EIP. As of January 31, 2022, the number of shares of our Class A common stock available for issuance under the 2013 EIP was 38,720,277 plus any shares of our Class B common stock subject to awards under the 2012 EIP and the 2007 Plan that expire or lapse unexercised or, with respect to shares issued pursuant to such awards, are forfeited or repurchased by us after the date of our IPO on October 15, 2013. The number of shares available for issuance under the 2013 EIP automatically increases on the first business day of each of our fiscal years, commencing in 2014, by a number equal to the least of (a) 13.75 million shares, (b) 5% of the shares of all classes of our common stock outstanding on the last business day of the prior fiscal year, or (c) the number of shares determined by our board of directors. During our fiscal year ended January 31, 2022, our board of directors determined to add 6,082,272 shares of common stock to the 2013 EIP. 2013 Employee Stock Purchase Plan Our Employee Stock Purchase Plan (ESPP) was adopted by our board of directors in August 2013 and our stockholders approved it in September 2013. The ESPP became effective as of our IPO registration statement on Form S-1, on October 15, 2013. Our ESPP is intended to qualify under Section 423 of the Internal Revenue Code of 1986, as amended (Code). The ESPP was approved with a reserve of 4 million shares of Class A common stock for future issuance under various terms provided for in the ESPP. As of January 31, 2022, the number of shares available for issuance under our ESPP was 4,897,856. The number of shares available for issuance under the ESPP automatically increases on the first business day of each of our fiscal years, commencing in 2014, by a number equal to the least of (a) 2.2 million shares, (b) 1% of the shares of all classes of our common stock outstanding on the last business day of the prior fiscal year or (c) the number of shares determined by our board of directors. During our fiscal year ended January 31, 2022, our board of directors determined no additional shares were to be made available for issuance under the ESPP. During active offering periods, our ESPP permits eligible employees to acquire shares of our common stock at 85% of the lower of the fair market value of our Class A common stock on the first day of the applicable offering period or the fair market value of our Class A common stock on the purchase date. Participants may purchase shares of common stock through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The initial offering period for our ESPP commenced on the date of our initial public offering and ended on June 15, 2014. We have not had any open offering periods subsequent to the initial offering period. Stock Option Activity The 2007 Stock Plan and the 2012 EIP provided, and the 2013 EIP provides, for the issuance of incentive and nonstatutory options to employees, consultants and non-employee directors. Options issued under and outside of the 2007 Plan generally are exercisable for periods not to exceed 10 years and generally vest over four five Number of shares Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate Options outstanding at January 31, 2021 12,761,289 $ 57.48 5.0 $ 2,794 Options granted 1,155,396 277.06 Options exercised (1,476,898) 34.90 Options forfeited/cancelled (349,265) 172.64 Options outstanding at January 31, 2022 12,090,522 $ 77.89 4.6 $ 1,964 Options vested and exercisable at January 31, 2022 7,203,834 $ 32.35 2.8 $ 1,472 Options vested and exercisable at January 31, 2022 and expected to vest thereafter 12,090,522 $ 77.89 4.6 $ 1,964 The options granted during the fiscal year ended January 31, 2022 were predominantly made in connection with our annual performance review cycle. The weighted average grant-date fair value of options granted was $108.42, $71.86, and $60.05 for the fiscal years ended January 31, 2022, 2021, and 2020, respectively. As of January 31, 2022, there was $229 million in unrecognized compensation cost related to unvested stock options granted under the 2012 Equity Incentive Plan and 2013 Equity Incentive Plan. This cost is expected to be recognized over a weighted average period of 2.6 years. As of January 31, 2022, we had authorized and unissued shares of common stock sufficient to satisfy exercises of stock options. Our closing stock price as reported on the New York Stock Exchange as of January 31, 2022, the last trading day of fiscal year 2022 was $236.54. The total intrinsic value of options exercised was approximately $363 million for the fiscal year ended January 31, 2022. Stock Option Valuation Assumptions The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented: Fiscal year ended January 31, 2022 2021 2020 Volatility 37% - 39% 39% - 42% 39% - 41% Expected term (in years) 6.25 6.25 - 7.25 5.64 - 6.61 Risk-free interest rate 0.70% - 1.60% 0.33% - 1.43% 1.39% - 2.52% Dividend yield —% —% —% Restricted Stock Units The 2013 EIP provides for the issuance of RSUs to employees. RSUs issued under the 2013 EIP generally vest over one Unreleased restricted stock units Weighted average grant date fair value Balance at January 31, 2021 1,032,215 $ 121.98 RSUs granted 518,172 277.79 RSUs vested (854,536) 173.01 RSUs forfeited / cancelled (76,463) 175.88 Balance at January 31, 2022 619,388 175.23 As of January 31, 2022, there was a total of $90 million in unrecognized compensation cost related to unvested RSUs. This cost is expected to be recognized over a weighted-average period of approximately 1.2 years. The total intrinsic value of RSUs vested was $246 million for the fiscal year ended January 31, 2022.

Other Income

Other Income	12 Months Ended
	Jan. 31, 2022
Other Income and Expenses [Abstract]
Other Income	Other Income Other income, net, consisted of the following (in thousands): Fiscal year ended January 31, 2022 2021 2020 Foreign currency (loss) gain $ (714) $ 2,275 $ (708) (Amortization) accretion on investments (7,201) (3,082) 3,001 Interest income, net 14,730 15,859 25,185 Miscellaneous income — 1,147 — Other income, net $ 6,815 $ 16,199 $ 27,478

Net Income per Share

Net Income per Share	12 Months Ended
	Jan. 31, 2022
Earnings Per Share [Abstract]
Net Income per Share	Net Income per Share Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted-average shares outstanding, including potentially dilutive shares of common equivalents outstanding during the period. The dilutive effect of potential shares of common stock are determined using the treasury stock method. The computation of fully diluted net income per share of Class A common stock assumes the conversion from Class B common stock, while the fully diluted net income per share of Class B common stock does not assume the conversion of those shares. The numerators and denominators of the basic and diluted net income per share computations for our common stock are calculated as follows (in thousands, except per share data): Fiscal year ended January 31, 2022 2021 2020 Class A Class B Class A Class B Class A Class B Basic Numerator Net income, basic $ 386,180 $ 41,210 $ 341,866 $ 38,132 $ 266,104 $ 35,014 Denominator Weighted average shares used in computing net income per share, basic 138,474 14,777 135,547 15,119 130,610 17,186 Net income per share, basic $ 2.79 $ 2.79 $ 2.52 $ 2.52 $ 2.04 $ 2.04 Diluted Numerator Net income, basic $ 386,180 $ 41,210 $ 341,866 $ 38,132 $ 266,104 $ 35,014 Reallocation as a result of conversion of Class B to Class A common stock: Net income, basic 41,210 — 38,132 — 35,014 — Reallocation of net income to Class B common stock — 21,480 — 21,409 — 17,652 Net income, diluted $ 427,390 $ 62,690 $ 379,998 $ 59,541 $ 301,118 $ 52,666 Denominator Number of shares used for basic net income per share computation 138,474 14,777 135,547 15,119 130,610 17,186 Conversion of Class B to Class A common stock 14,777 — 15,119 — 17,186 — Effect of potentially dilutive common shares 9,026 9,026 10,066 10,066 10,500 10,500 Weighted average shares used in computing net income per share, diluted 162,277 23,803 160,732 25,185 158,296 27,686 Net income per share, diluted $ 2.63 $ 2.63 $ 2.36 $ 2.36 $ 1.90 $ 1.90 Potential common share equivalents excluded where the inclusion would be anti-dilutive are as follows: Fiscal year ended January 31, 2022 2021 2020 Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive 958,476 1,045,222 1,461,255

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation IQVIA Litigation Matters Veeva OpenData and Veeva Network Action. On January 10, 2017, IQVIA Inc. (formerly Quintiles IMS Incorporated) and IMS Software Services, Ltd. (collectively, “IQVIA”) filed a complaint against us in the U.S. District Court for the District of New Jersey (IQVIA Inc. v. Veeva Systems Inc. (No. 2:17-cv-00177)) (OpenData and Network Action). In the complaint, IQVIA alleges that we used unauthorized access to proprietary IQVIA data to improve our software and data products and that our software is designed to steal IQVIA trade secrets. IQVIA further alleges that we have intentionally gained unauthorized access to IQVIA proprietary information to gain an unfair advantage in marketing our products and that we have made false statements concerning IQVIA’s conduct and our data security capabilities. IQVIA asserts claims under both federal and state misappropriation of trade secret laws, federal false advertising law, and common law claims for unjust enrichment, tortious interference, and unfair trade practices. The complaint seeks declaratory and injunctive relief and unspecified monetary damages. On March 13, 2017, we filed our answer denying IQVIA's claims and filed counterclaims. Our counterclaims allege that IQVIA, as the dominant provider of data for life sciences companies, has abused monopoly power to exclude Veeva OpenData and Veeva Network from their respective markets. The counterclaims allege that IQVIA has engaged in various tactics to prevent customers from using our applications and has deliberately raised costs and increased the difficulty of attempting to switch from IQVIA data to our data products. As amended, our counterclaims assert federal and state antitrust claims, as well as claims under California’s Unfair Practices Act and common law claims for intentional interference with contractual relations, intentional interference with prospective economic advantage, and negligent misrepresentation. The counterclaims seek injunctive relief, monetary damages exceeding $200 million, and attorneys’ fees. On October 3, 2018, the court denied IQVIA’s motion to dismiss our antitrust claims. On February 18, 2020, IQVIA filed a motion for sanctions against Veeva, seeking default judgment and dismissal and, in the alternative, an adverse inference at trial related to discovery disputes. On May 7, 2021, the special master appointed to oversee litigation discovery ruled against IQVIA’s request for default judgment and dismissal and ruled in IQVIA’s favor with respect to certain other matters, including recommending to the trial judge that a permissive adverse inference instruction be issued to the jury with respect to certain documents that were not preserved by Veeva. Should the trial judge accept the recommendation, the jury would be permitted, but not required, to infer that certain evidence not preserved by Veeva would have been unfavorable to Veeva, if the jury first concludes that Veeva controlled the evidence, that the evidence was relevant, and that Veeva should have preserved the evidence. The jury is also likely to be instructed that it may also consider whether the non-preserved evidence was duplicative of other evidence produced by Veeva and whether Veeva’s conduct was reasonable in light of all circumstances. Veeva was also ordered to pay IQVIA’s fees and expenses incurred in connection with portions of its sanctions motion. On June 4, 2021, we appealed the special master’s ruling and IQVIA’s fee award to the federal district court judge. Fact discovery is largely complete and we expect to complete expert discovery by November 2022.While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, and we are unable to make a meaningful estimate of the amount or range of gain or loss, if any, that could result from the OpenData and Network Action, we believe that IQVIA’s claims lack merit and that our counterclaims warrant injunctive relief and monetary damages for Veeva. Veeva Nitro Action. On July 17, 2019, IQVIA filed a lawsuit in the U.S. District Court for the District of New Jersey (IQVIA Inc. v. Veeva Systems Inc. (No. 2:19-cv-15517)) (IQVIA Declaratory Action) seeking a declaratory judgment that IQVIA is not liable to Veeva for disallowing use of IQVIA’s data products in Veeva Nitro or any later-introduced Veeva software products. The IQVIA Declaratory Action does not seek any monetary relief. On July 18, 2019, we filed a lawsuit against IQVIA in the U.S. District Court for the Northern District of California (Veeva Systems Inc. v. IQVIA Inc. (No. 3:19-cv-04137)) (Veeva Nitro Action), alleging that IQVIA engaged in anticompetitive conduct as to Veeva Nitro. Our complaint asserts federal and state antitrust claims, as well as claims under California’s Unfair Competition Law and common law claims for intentional interference with contractual relations and intentional interference with prospective economic advantage. The complaint seeks injunctive relief and monetary damages. IQVIA filed its answer and affirmative defenses on September 5, 2019. On September 26, 2019, the Northern District of California transferred the Veeva Nitro Action to the District of New Jersey (Veeva Systems Inc. v. IQVIA Inc. (No. 2:19-cv-18558)). On March 24, 2020, we amended our complaint in the Veeva Nitro Action to include allegations of IQVIA’s anticompetitive conduct as to additional Veeva software applications, such as Veeva Andi, Veeva Align, and Veeva Vault MedComms; additional examples of IQVIA’s monopolistic behavior against Veeva Nitro; IQVIA’s unlawful access of Veeva’s proprietary software products; and a request for declaratory relief. IQVIA answered the amended complaint on May 22, 2020. On August 21, 2020, the District of New Jersey consolidated the Veeva Nitro Action and IQVIA Declaratory Action, and stayed both actions pending conclusion of the OpenData and Network Action. On September 21, 2021, the court lifted the stay. We expect to complete fact discovery by June 2022, and to complete expert discovery by November 2022. On March 22, 2022, IQVIA submitted a letter seeking permission to file a motion for partial judgment on the pleadings under Federal Rule of Civil Procedure 12(c). If filed, the motion would seek judgment against Veeva on four of five federal antitrust claims and the common law claim for intentional interference with contractual relations. The court has not ruled on IQVIA's request. While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, we believe that our claims warrant injunctive and declaratory relief and monetary damages for Veeva and against IQVIA. Fee Arrangements Related to the IQVIA Litigation Matters. We have entered into partial contingency fee arrangements with certain law firms representing us in the IQVIA litigations. Pursuant to those arrangements, such law firms are entitled to an agreed portion of any damages we recover from IQVIA (Contingency Fees) or may be entitled to payment of additional fees from us based on the achievement of certain outcomes (Success Fees). While it is reasonably possible that we may incur such Success Fees, we are unable to make an estimate of any such liability and have not accrued any liability related to Success Fees at this time. Medidata Litigation Matter On January 26, 2017, Medidata Solutions, Inc. filed a complaint in the U.S. District Court for the Southern District of New York ( Medidata Solutions, Inc. v. Veeva Systems Inc. et al. (No. 1:17-cv-00589)) against us and five individual Veeva employees who previously worked for Medidata (“Individual Employees”). The complaint alleged that we induced and conspired with the Individual Employees to breach their employment agreements, including non-compete and confidentiality provisions, and to misappropriate Medidata’s confidential and trade secret information. The complaint sought declaratory and injunctive relief, unspecified monetary damages, and attorneys’ fees. Medidata has since amended its complaint twice, asserting the same claims with additional factual allegations, and has voluntarily dismissed the Individual Defendants without prejudice. Fact discovery is now completed. On April 24, 2020, Medidata filed a motion for partial summary judgment on its claims for trade secret misappropriation as well as several of Veeva’s affirmative defenses. On May 15, 2020, we filed a motion for summary judgment on all of Medidata’s claims. On February 9, 2021, the court issued its ruling granting summary judgment in favor of Veeva as to certain of Medidata's claims and in favor of Medidata as to certain of Veeva's affirmative defenses. The trial in this matter is currently set for July 18, 2022. While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, and we are unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome, we believe that Medidata’s claims lack merit. Other Litigation Matters From time to time, we may be involved in other legal proceedings and subject to claims incident to the ordinary course of business. Although the results of such legal proceedings and claims cannot be predicted with certainty, we believe we are not currently a party to any other legal proceedings, the outcome of which, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial position. Regardless of the outcome, such proceedings can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

Revenues by Product

Revenues by Product	12 Months Ended
	Jan. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenues by Product	Revenues by Product Prior to the fiscal quarter ended October 31, 2021, we grouped our revenues into two product areas: Commercial Cloud and Vault. During the fiscal quarter ended October 31, 2021, we changed the product areas under which we group revenues to Commercial Solutions and R&D Solutions to better align with how we manage our business and to reflect the principal functions served by our products. Commercial Solutions consist of our cloud software, data, and analytics products built specifically to more efficiently and effectively commercialize our customers’ products. R&D Solutions consist of our clinical, quality, regulatory, and safety products. Specifically, revenues attributable to Vault PromoMats and Vault MedComms, applications used for commercial operations, are now reflected in Commercial Solutions. The prior period revenue balances in the table below have been adjusted to reflect the current period presentation of our product areas. There were no changes to the aggregate amounts reported within our consolidated statements of comprehensive income. Total revenues consist of the following (in thousands): Fiscal year ended January 31, 2022 2021 2020 Subscription services Commercial Solutions $ 876,458 $ 744,856 $ 593,562 R&D Solutions 607,518 434,630 302,732 Total subscription services 1,483,976 1,179,486 896,294 Professional services Commercial Solutions 165,086 142,003 103,825 R&D Solutions 201,715 143,580 103,962 Total professional services 366,801 285,583 207,787 Total revenues $ 1,850,777 $ 1,465,069 $ 1,104,081

Information about Geographic Ar

Information about Geographic Areas	12 Months Ended
	Jan. 31, 2022
Segment Reporting [Abstract]
Information about Geographic Areas	Information about Geographic Areas We track and allocate revenues by principal geographic area rather than by individual country, which makes it impractical to disclose revenues for the United States or other specific foreign countries. We measure subscription services revenue primarily by the estimated location of the end users in each geographic area for our Commercial Solutions and primarily by the estimated location of usage in each geographic area for our R&D Solutions. We measure professional services revenue primarily by the location of the resources performing the professional services. Total revenues by geographic area were as follows for the periods shown below (in thousands): Fiscal year ended January 31, 2022 2021 2020 North America $ 1,063,770 $ 838,192 $ 607,704 Europe 509,127 400,790 310,215 Asia Pacific 225,968 183,848 151,052 Middle East, Africa, and Latin America 51,912 42,239 35,110 Total revenues $ 1,850,777 $ 1,465,069 $ 1,104,081 Long-lived assets by geographic area are as follows as of the periods shown below (in thousands): January 31, 2022 2021 North America $ 45,625 $ 46,285 Europe 6,135 5,525 Asia Pacific 1,335 1,359 Middle East, Africa, and Latin America 1,400 481 Total long-lived assets $ 54,495 $ 53,650

401(k) Plan

401(k) Plan	12 Months Ended
	Jan. 31, 2022
Retirement Benefits [Abstract]
401(k) Plan	401(k) PlanWe have a qualified defined contribution plan under Section 401(k) of the Internal Revenue Code covering eligible employees as well as a Registered Retirement Savings Plan (RRSP) for eligible employees in Canada. Under the 401(k) plan, we match up to $2,000 per employee per year. Under the RRSP plan, we also match up to $2,000 per employee per year. For the fiscal years ended January 31, 2022, 2021, and 2020, total expense related to these plans was $7 million, $6 million, and $4 million, respectively.

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Description of Business	Description of Business Veeva is the leading provider of industry cloud solutions for the global life sciences industry. We were founded in 2007 on the premise that industry-specific cloud solutions could best address the operating challenges and regulatory requirements of life sciences companies. Our offerings span cloud software, data, analytics, professional services, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) to commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, quality, regulatory, and safety functions help life sciences companies streamline their end-to-end product development processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. We also bring the benefits of our content and data management solutions to a set of customers outside of life sciences in other regulated industries, including, for example, consumer goods, chemicals, and cosmetics. Our fiscal year end is January 31.
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation These consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding annual financial reporting and include the accounts of our wholly-owned subsidiaries after elimination of intercompany accounts and transactions.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to: • the standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations; • the determination of the period of benefit for amortization of deferred costs; • the realizability of deferred income tax assets and liabilities; • the fair value of our stock-based awards. As future events cannot be determined with precision, actual results could differ significantly from those estimates.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. We define the term “chief operating decision maker” to be our Chief Executive Officer. Our Chief Executive Officer reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Since we operate in one operating segment, all required financial segment information can be found in the consolidated financial statements.
Revenue Recognition	Revenue Recognition We derive our revenues primarily from subscription services and professional services. Subscription services revenues consist of fees from customers accessing our cloud-based software solutions and fees for our data solutions. Professional services and other revenues consist primarily of fees from implementation services, configuration, data services, training, and managed services related to our solutions. Revenues are recognized when control of these services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. We determine revenue recognition through the following steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, we satisfy a performance obligation. Our subscription services agreements are generally non-cancelable during the term, although customers typically have the right to terminate their agreements for cause in the event of material breach. Subscription Services Revenues Subscription services revenues are recognized ratably over the respective non-cancelable subscription term because of the continuous transfer of control to the customer. Our subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Professional Services and Other Revenues The majority of our professional services arrangements are billed on a time and materials basis and revenues are recognized over time based on time incurred and contractually agreed upon rates. Certain professional services revenues are billed on a fixed fee basis and revenues are typically recognized over time as the services are delivered based on time incurred. Data services and training revenues are generally recognized as the services are performed. Contracts with Multiple Performance Obligations Some of our contracts with customers contain multiple performance obligations. For these contracts, we account for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions and other factors, including other groupings such as customer type and geography.
Deferred Costs	Deferred Costs Deferred costs represents sales commissions associated with obtaining a contract with a customer. These costs are deferred and then amortized over a period of benefit that we have determined to be one
Certain Risks and Concentrations of Credit Risk	Certain Risks and Concentrations of Credit Risk Our revenues are derived from subscription services, professional services and other services delivered primarily to the life sciences industry. We operate in markets that are highly competitive and rapidly changing. Significant technological changes, shifting customer needs, the emergence of competitive products or services with new capabilities, and other factors could negatively impact our future operating results. Our financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and trade accounts receivable. Our cash equivalents and short-term investments are held by established financial institutions. We have established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these financial institutions may significantly exceed federally insured limits. We do not require collateral from our customers and generally require payment within 30 days to 60 days of billing.
Cash Equivalents	Cash Equivalents We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Short-term Investments	Short-term Investments Our short-term investments are classified as available-for-sale and recorded at estimated fair value. Unrealized gains and losses for available-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. We evaluate our investments to assess whether those with unrealized loss positions are other than temporarily impaired. We consider impairments to be other than temporary if they are related to deterioration in credit risk or if it is likely we will sell the securities before the recovery of their cost basis. Realized gains and losses and declines in value judged to be other than temporary are determined based on the specific identification method and are reported in other income, net, in the consolidated statements of comprehensive income. Interest, amortization of premiums, and accretion of discount on all short-term investments are also included as a component of other income, net, in the consolidated statements of comprehensive income. We may sell our short-term investments at any time, without significant penalty, for use in current operations or for other purposes, even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond 12 months, as current assets in the accompanying consolidated balance sheets.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount, net of allowance for doubtful accounts, which is not material.
Property and Equipment	Property and EquipmentProperty and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets and commences once the asset is placed in service or ready for its intended use. Land is not depreciated.
Leases	Leases We have operating leases for corporate offices. Additionally, we are the sublessor for certain office space. We adopted Accounting Standards Update (ASU) 2016-02 “ Leases ” (Topic 842) using the modified retrospective method as of February 1, 2019 with an immaterial amount of cumulative effect adjustment recorded to our retained earnings. Subsequent to our adoption of Topic 842, we recognize lease right-of-use assets and liabilities at the commencement date based on the present value of lease payments over the lease term. We use an estimate of our discount rate based on the information available at the lease commencement date in determining the present value of lease payments, unless the implicit rate is readily determinable. The lease right-of-use assets also include any lease payments made and exclude lease incentives such as tenant improvement allowances. Options to extend or terminate the lease are included in the lease term when it is reasonably certain that we will exercise the extension or termination option. Our operating leases typically include non-lease components such as common-area maintenance costs. We have elected to exclude non-lease components from lease payments for the purpose of calculating lease right-of-use assets and liabilities and these are expensed as incurred as variable lease payments. Leases with a term of one year or less are not recognized on our consolidated balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.
Internal-Use Software	Internal-Use Software We capitalize certain costs incurred for the development of computer software for internal use. We capitalize these costs during the development of the project, when it is determined that it is probable that the project will be completed and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training, and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life of three years, and the amortization expense is recorded as a component of cost of subscription services. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill is tested for impairment annually in the fourth quarter of each year or if circumstances indicate the carrying value of goodwill is impaired. We have one reporting unit and evaluate goodwill for impairment at the entity level. We completed our annual impairment test in our fourth quarter of the fiscal year ended January 31, 2022, which resulted in no impairment of the goodwill balance. All other intangible assets associated with purchased intangibles, consisting of existing technology, databases, customer relationships, software, trade names and trademarks, data supplier and partner relationships, non-competition agreements, brand, and backlog are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. Amortization expense related to existing technology, databases, data supplier and partner relationships, software, and backlog is included in cost of subscription services. Amortization expense related to customer relationships, trade names and trademarks, and brand are included in sales and marketing expense. Amortization expense related to non-competition agreements are included in both general and administrative and research and development expense.
Long-Lived Assets	Long-Lived Assets Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, we first compare undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
Business Combinations	Business Combinations The purchase price in a business combination is assigned to the estimated acquisition date fair values of the tangible and intangible assets acquired and the liabilities assumed with the residual recorded as goodwill. Critical estimates in valuing certain of the intangible assets include, but are not limited to, the net present value of future expected cash flows, future revenue growth, margins, customer retention rates, technology life, royalty rates, expected use of acquired assets, and discount rates.
Stock-based Compensation	Stock-based Compensation We recognize compensation expense for all stock-based awards, including stock options and restricted stock units (RSUs), based on the estimate of fair value of the award at the grant date. The fair value of each option award is estimated on the grant date using either a Black-Scholes option-pricing model or a Monte Carlo simulation, to the extent market conditions exist, and a single option award approach. These models require that at the date of grant we determine the fair value of the underlying common stock, the expected term of the award, the expected volatility of the price of our common stock, risk-free interest rates, and expected dividend yield of our common stock. The fair value of each RSU award is measured based on the closing stock price of our common stock on the date of grant. We account for forfeitures as they occur. The compensation expense is recognized using a straight-line basis over the requisite service periods of the awards, which is one four
Cost of Revenues	Cost of Revenues Cost of subscription services revenues consists of expenses related to our computing infrastructure provided by third parties, including salesforce.com and Amazon Web Services, personnel-related costs associated with hosting our subscription services and providing support including our data stewards, data acquisition costs, and allocated overhead, amortization expense associated with capitalized internal-use software related to our subscription services, and amortization expense associated with purchased intangibles related to our subscription services. Cost of subscription services revenues for Veeva CRM and certain of our multichannel customer relationship management applications include fees paid to salesforce.com for our use of the Salesforce Platform and the associated hosting infrastructure and data center operations that are provided by salesforce.com. Cost of professional services and other revenues consists primarily of employee-related expenses associated with providing these services, including salaries, benefits and stock-based compensation expense, the cost of third-party subcontractors, travel costs, and allocated overhead.
Advertising Expenses	Advertising Expenses Advertising expenditures are expensed as incurred and were immaterial for each of the years presented.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We regularly assess the realizability of our deferred tax assets and establish a valuation allowance if it is more likely than not that some or all of our deferred tax assets will not be realized. We evaluate and weigh all available positive and negative evidence such as historic results, future reversals of existing deferred tax liabilities, projected future taxable income, as well as prudent and feasible tax-planning strategies. Generally, more weight is given to objectively verifiable evidence such as the cumulative income in recent years.
Foreign Currency Exchange	Foreign Currency Exchange Adjustments resulting from translating financial statements for those entities that do not have U.S. dollars as their functional currency are recorded as part of a separate component of the consolidated statements of comprehensive income. All assets and liabilities denominated in currencies other than U.S. dollars are translated into the U.S. dollar functional currency at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average exchange rate during the period. Equity transactions are translated using historical exchange rates. Foreign currency transaction gains and losses are included in the consolidated statements of comprehensive income for the period.
Indemnification	Indemnification Our contracts generally include provisions for indemnifying customers against liabilities if our solutions infringe a third party’s intellectual property rights, and we may also incur liabilities if we breach the security and/or confidentiality obligations in our contracts. To date, we have not incurred any material costs, and we have not accrued any liabilities in the accompanying consolidated financial statements as a result of these obligations.
Loss Contingencies	Loss Contingencies Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
New Accounting Pronouncements Adopted in Fiscal 2022	New Accounting Pronouncements Adopted in Fiscal 2022 Income Taxes In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ” which simplifies accounting guidance for certain tax matters. We adopted this standard effective February 1, 2021. The adoption of this new standard did not have a material impact on our consolidated financial statements.
Fair Value Measurements	Financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires management to make judgments and considers factors specific to the asset or liability.
Net Income per Share Attributable to Common Stockholders	Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted-average shares outstanding, including potentially dilutive shares of common equivalents outstanding during the period. The dilutive effect of potential shares of common stock are determined using the treasury stock method. The computation of fully diluted net income per share of Class A common stock assumes the conversion from Class B common stock, while the fully diluted net income per share of Class B common stock does not assume the conversion of those shares.

Summary of Business and Signi_3

Summary of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Schedule of Certain Risks and Concentrations of Credit Risk	The following customers individually exceeded 10% of total accounts receivable as of the dates shown: January 31, 2022 2021 Customer 1 10% 12% Customer 2 10% * * Does not exceed 10%.
Schedule of Estimated Useful Lives of Property and Equipment	The estimated useful lives by asset classification are as follows: Building 30 years Land and building improvements 10 years (land improvements) and estimated useful life of building (building improvements) Equipment and computers 3 years Furniture and fixtures 5 years Leasehold improvements Shorter of remaining life of the lease term or estimated useful life Property and equipment, net consists of the following as of the dates shown (in thousands): January 31, 2022 2021 Land $ 3,040 $ 3,040 Building 20,984 20,984 Land improvements and building improvements 22,392 22,392 Equipment and computers 3,581 8,847 Furniture and fixtures 15,040 13,452 Leasehold improvements 19,002 13,945 Construction in progress 730 606 84,769 83,266 Less accumulated depreciation (30,274) (29,616) Total property and equipment, net $ 54,495 $ 53,650

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jan. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Estimated Fair Values of Assets and Liabilities Assumed	The following table summarizes the estimated fair values of the assets acquired, useful lives, and liabilities assumed at the acquisition date (in thousands): Useful life Fair value Net assets acquired $ 4,766 Identifiable intangible assets: Customer relationships 10 years 70,100 Existing technology 6 years 19,200 Trade name and trademarks 5 years 13,200 Other intangibles 1 to 7 years 6,000 Total purchased intangible assets 108,500 Goodwill 314,642 Total purchase consideration $ 427,908 The following table summarizes the estimated fair values of the assets acquired, useful lives, and liabilities assumed at the acquisition date (in thousands): Useful life Fair value Net assets acquired $ 1,221 Identifiable intangible assets: Customer relationships 10 years $7,700 Existing technology 6 years 3,300 Trade name and trademarks 5 years 700 Total purchased intangible assets 11,700 Goodwill 28,083 Total purchase consideration $ 41,004
Schedule of Pro Forma Information from Business Acquisition	Accordingly, these unaudited pro forma results are presented for information purpose only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations (in thousands): Fiscal Year Ended January 31, 2020 Pro forma revenues $ 1,153,497 Pro forma net income $ 278,215 Pro forma net income per share: Basic $ 1.88 Diluted $ 1.76

Short-Term Investments (Tables)

Short-Term Investments (Tables)	12 Months Ended
	Jan. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Short-Term Investments	At January 31, 2022, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 13,500 $ — $ (15) $ 13,485 Asset-backed securities 191,676 45 (1,432) 190,289 Commercial paper 29,432 — (2) 29,430 Corporate notes and bonds 669,489 276 (5,856) 663,909 Foreign government bonds 24,577 13 (179) 24,411 U.S. agency obligations 27,978 12 (254) 27,736 U.S. treasury securities 290,513 46 (1,755) 288,804 Total available-for-sale securities $ 1,247,165 $ 392 $ (9,493) $ 1,238,064 At January 31, 2021, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 17,350 $ 15 $ (1) $ 17,364 Asset-backed securities 125,833 745 (2) 126,576 Commercial paper 57,390 8 (2) 57,396 Corporate notes and bonds 428,710 2,360 (23) 431,047 Foreign government bonds 31,855 45 (2) 31,898 U.S. agency obligations 52,756 119 — 52,875 U.S. treasury securities 215,379 587 — 215,966 Total available-for-sale securities $ 929,273 $ 3,879 $ (30) $ 933,122
Summary of Estimated Fair Value of Short-Term Investments, Designated as Available-for-Sale and Classified by Contractual Maturity	The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates shown (in thousands): January 31, 2022 2021 Due in one year or less $ 457,948 $ 428,155 Due in greater than one year 780,116 504,967 Total short-term investments $ 1,238,064 $ 933,122
Schedule of Fair Values and Gross Unrealized Loss Position of Available-for-Sale Securities Aggregated by Investment Category	The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2022 (in thousands): Held for less than 12 months Fair value Gross unrealized losses Certificates of deposits $ 5,985 $ (15) Asset-backed securities 177,056 (1,432) Commercial paper 17,190 (2) Corporate notes and bonds 571,099 (5,856) Foreign government bonds 19,594 (179) U.S. agency obligations 24,725 (254) U.S. treasury securities 247,509 (1,756) The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2021 (in thousands): Held for less than 12 months Fair value Gross unrealized losses Certificates of deposits $ 3,749 $ (2) Asset-backed securities 3,318 (1) Commercial paper 17,626 (2) Corporate notes and bonds 29,558 (23) Foreign government bonds 2,679 (2)

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Jan. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	The estimated useful lives by asset classification are as follows: Building 30 years Land and building improvements 10 years (land improvements) and estimated useful life of building (building improvements) Equipment and computers 3 years Furniture and fixtures 5 years Leasehold improvements Shorter of remaining life of the lease term or estimated useful life Property and equipment, net consists of the following as of the dates shown (in thousands): January 31, 2022 2021 Land $ 3,040 $ 3,040 Building 20,984 20,984 Land improvements and building improvements 22,392 22,392 Equipment and computers 3,581 8,847 Furniture and fixtures 15,040 13,452 Leasehold improvements 19,002 13,945 Construction in progress 730 606 84,769 83,266 Less accumulated depreciation (30,274) (29,616) Total property and equipment, net $ 54,495 $ 53,650

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Jan. 31, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Goodwill	The following schedule presents the details of goodwill as of January 31, 2022 (dollar amounts in thousands): Balance as of January 31, 2020 $ 438,529 Purchase price goodwill reduction from Crossix tax adjustments (2,500) Balance as of January 31, 2021 436,029 Goodwill from business acquisitions $ 3,848 Balance as of January 31, 2022 $ 439,877
Details of Intangible Assets	The following schedule presents the details of intangible assets as of January 31, 2022 (dollar amounts in thousands): January 31, 2022 Gross carrying amount Accumulated amortization Net Remaining useful life (in years) Existing technology $ 28,580 $ (12,187) $ 16,393 3.9 Customer relationships 113,157 (38,829) 74,328 7.0 Trade name and trademarks 13,900 (6,645) 7,255 2.8 Other intangibles 21,405 (17,441) 3,964 3.8 Total intangible assets $ 177,042 $ (75,102) $ 101,940 The following schedule presents the details of intangible assets as of January 31, 2021 (dollar amounts in thousands): January 31, 2021 Gross Accumulated Net Remaining Existing technology $ 26,180 $ (8,367) $ 17,813 4.8 Customer relationships 110,643 (27,741) 82,902 8.0 Trade name and trademarks 13,900 (4,005) 9,895 3.8 Other intangibles 20,453 (16,468) 3,985 5.1 Total intangible assets $ 171,176 $ (56,581) $ 114,595
Estimated Amortization Expense	As of January 31, 2022, the estimated amortization expense for intangible assets, for the next five years and thereafter is as follows (in thousands): Fiscal 2023 $ 19,463 Fiscal 2024 19,459 Fiscal 2025 18,557 Fiscal 2026 14,147 Fiscal 2027 8,922 Thereafter 21,392 Total $ 101,940

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Jan. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following as of the dates shown (in thousands): January 31, 2022 2021 Accrued commissions $ 8,556 $ 7,498 Accrued bonus 4,677 4,134 Accrued vacation 5,546 4,716 Payroll tax payable 9,487 10,250 Accrued other compensation and benefits 5,568 3,812 Total accrued compensation and benefits $ 33,834 $ 30,410 Accrued fees payable to salesforce.com $ 6,521 $ 6,381 Taxes payable 9,743 13,598 Accrued third-party professional services subcontractors' fees 1,961 1,515 Other accrued expenses 17,884 9,488 Total accrued expenses and other current liabilities $ 36,109 $ 30,982

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jan. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of January 31, 2022 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 428,411 $ — $ 428,411 Corporate notes and bonds — 5,853 5,853 Asset-backed securities — 2,568 2,568 Short-term investments: Certificates of deposits — 13,485 13,485 Asset-backed securities — 190,289 190,289 Commercial paper — 29,430 29,430 Corporate notes and bonds — 663,909 663,909 Foreign government bonds — 24,411 24,411 U.S. agency obligations — 27,736 27,736 U.S. Treasury securities — 288,804 288,804 Foreign currency derivative contracts — 1,222 1,222 Total financial assets $ 428,411 $ 1,247,707 $ 1,676,118 The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2021 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 259,937 $ — $ 259,937 U.S. Treasury securities — 15,520 15,520 Short-term investments: Certificates of deposits — 17,364 17,364 Asset-backed securities — 126,576 126,576 Commercial paper — 57,396 57,396 Corporate notes and bonds — 431,047 431,047 Foreign government bonds — 31,898 31,898 U.S. agency obligations — 52,875 52,875 U.S. Treasury securities — 215,966 215,966 Foreign currency derivative contracts — 440 440 Total financial assets $ 259,937 $ 949,082 $ 1,209,019 Liabilities Foreign currency derivative contracts $ — $ 72 $ 72 Total financial liabilities $ — $ 72 $ 72
Summary Fair Value of Outstanding Derivative Instruments	The fair value of our outstanding derivative instruments is summarized below (in thousands): January 31, 2022 2021 Notional amount of foreign currency derivative contracts $ 87,097 $ 52,516 Fair value of foreign currency derivative contracts 85,876 52,148
Summary of Outstanding Balance Sheet Hedges	Derivatives not designated as hedging instruments are presented as components of the following balance sheet items for the periods shown as follows (in thousands): January 31, Balance sheet presentation 2022 2021 Foreign currency derivative contracts - assets Prepaid expenses and other current assets $ 1,222 $ 440 Foreign currency derivative contracts - liabilities Accrued expenses — 72

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jan. 31, 2022
Income Tax Disclosure [Abstract]
Components of Income before Income Taxes	The components of income before income taxes by U.S. and foreign jurisdictions were as follows for the periods shown (in thousands): Fiscal year ended January 31, 2022 2021 2020 United States $ 487,962 $ 378,042 $ 305,339 Foreign 24,349 15,951 8,358 Total $ 512,311 $ 393,993 $ 313,697
Components of Provision for Income Taxes	Provision for income taxes consisted of the following for the periods shown (in thousands): Fiscal year ended January 31, 2022 2021 2020 Current provision: Federal $ 53,426 $ 7,108 $ 11,143 State 12,580 4,763 4,695 Foreign 7,837 2,825 3,404 Total current provision 73,843 14,696 19,242 Deferred provision: Federal 1,870 (816) (1,063) State 945 681 (517) Foreign 8,264 (566) (5,083) Total deferred provision 11,079 (701) (6,663) Provision for income taxes $ 84,921 $ 13,995 $ 12,579
Reconciliation of Statutory Federal Income Tax to Effective Tax	Provision for income taxes differed from the amount computed by applying the federal statutory income tax rate of 21% for each of the fiscal years ended January 31, 2022, 2021, and 2020 to income before income taxes as a result of the following for the periods shown (in thousands): Fiscal year ended January 31, 2022 2021 2020 Federal tax statutory tax rate $ 107,585 $ 82,739 $ 65,876 State taxes 11,035 4,401 3,035 Tax credits (25,968) (24,617) (23,468) Stock-based compensation (29,715) (54,488) (34,569) Valuation allowance 19,402 10,269 7,408 Foreign derived intangible income deduction (FDII) (3,406) (5,134) (4,836) Other (1) 5,988 825 (867) Provision for income taxes $ 84,921 $ 13,995 $ 12,579 (1) Prior period balances were adjusted to conform with current period presentation.
Components of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and liabilities related to the following (in thousands): January 31, 2022 2021 Deferred tax assets: Accruals and reserves $ 7,068 $ 13,494 Capitalized expenditures 10,477 — Stock-based compensation 16,615 11,486 Net operating loss carryforward 21,850 29,318 Tax credit carryforward 34,725 29,624 Lease liabilities 13,813 15,932 Other (1) 2,955 977 Gross deferred tax assets 107,503 100,831 Valuation allowance (48,484) (31,318) Total deferred tax assets 59,019 69,513 Deferred tax liabilities: Intangible assets (31,200) (30,253) Lease right-of-use assets (12,497) (14,438) Deferred costs (1) (10,552) (11,481) Other (1) (1,889) (1,076) Total deferred tax liabilities (56,138) (57,248) Net deferred tax assets $ 2,881 $ 12,265 (1) Prior period balances were adjusted to conform with current period presentation.
Summary of Changes in Total Gross Amount of Unrecognized Tax Benefits	The aggregate changes in our total gross amount of unrecognized tax benefits are summarized as follows for the periods shown (in thousands): Fiscal year ended January 31, 2022 2021 2020 Beginning balance $ 18,628 $ 14,515 $ 12,597 Increases related to tax positions taken during the prior period 3,218 96 796 Increases related to tax positions taken during the current period 4,122 4,126 3,420 Decreases related to tax positions taken during the prior period — (51) (128) Audit settlements (195) — — Lapse of statute of limitations (532) (58) (2,170) Ending balance $ 25,241 $ 18,628 $ 14,515

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jan. 31, 2022
Leases [Abstract]
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows (in thousands): Fiscal year ended January 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities $ 13,800 $ 11,401 Right-of-use assets obtained in exchange for lease obligations: Operating leases 3,848 12,214
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate): January 31, 2022 2021 Lease right-of-use assets $ 49,640 $ 56,917 Lease liabilities $ 10,981 $ 11,347 Lease liabilities, noncurrent 43,607 51,393 Total operating lease liabilities $ 54,588 $ 62,740 Weighted Average Remaining Lease Term 6.0 years 6.7 years Weighted Average Discount Rate 3.7 % 3.8 %
Maturity of Operating Lease Liabilities	As of January 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal 2023 $ 12,143 Fiscal 2024 11,942 Fiscal 2025 8,951 Fiscal 2026 7,251 Fiscal 2027 6,316 Thereafter 14,674 Total operating lease payments 61,277 Less imputed interest 6,689 Total operating lease liabilities $ 54,588

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jan. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the fiscal year ended January 31, 2022 is as follows: Number of shares Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate Options outstanding at January 31, 2021 12,761,289 $ 57.48 5.0 $ 2,794 Options granted 1,155,396 277.06 Options exercised (1,476,898) 34.90 Options forfeited/cancelled (349,265) 172.64 Options outstanding at January 31, 2022 12,090,522 $ 77.89 4.6 $ 1,964 Options vested and exercisable at January 31, 2022 7,203,834 $ 32.35 2.8 $ 1,472 Options vested and exercisable at January 31, 2022 and expected to vest thereafter 12,090,522 $ 77.89 4.6 $ 1,964
Schedule of Weighted-Average Assumptions Used to Estimate Grant Date Fair Value of Options Granted	The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented: Fiscal year ended January 31, 2022 2021 2020 Volatility 37% - 39% 39% - 42% 39% - 41% Expected term (in years) 6.25 6.25 - 7.25 5.64 - 6.61 Risk-free interest rate 0.70% - 1.60% 0.33% - 1.43% 1.39% - 2.52% Dividend yield —% —% —%
Summary of Restricted Stock Unit (RSU) Activity	A summary of RSU activity for the fiscal year ended January 31, 2022 is as follows: Unreleased restricted stock units Weighted average grant date fair value Balance at January 31, 2021 1,032,215 $ 121.98 RSUs granted 518,172 277.79 RSUs vested (854,536) 173.01 RSUs forfeited / cancelled (76,463) 175.88 Balance at January 31, 2022 619,388 175.23

Other Income (Tables)

Other Income (Tables)	12 Months Ended
	Jan. 31, 2022
Other Income and Expenses [Abstract]
Schedule of Other Income	Other income, net, consisted of the following (in thousands): Fiscal year ended January 31, 2022 2021 2020 Foreign currency (loss) gain $ (714) $ 2,275 $ (708) (Amortization) accretion on investments (7,201) (3,082) 3,001 Interest income, net 14,730 15,859 25,185 Miscellaneous income — 1,147 — Other income, net $ 6,815 $ 16,199 $ 27,478

Net Income per Share (Tables)

Net Income per Share (Tables)	12 Months Ended
	Jan. 31, 2022
Earnings Per Share [Abstract]
Numerators and Denominators of the Basic and Diluted EPS Computations for Common Stock	The numerators and denominators of the basic and diluted net income per share computations for our common stock are calculated as follows (in thousands, except per share data): Fiscal year ended January 31, 2022 2021 2020 Class A Class B Class A Class B Class A Class B Basic Numerator Net income, basic $ 386,180 $ 41,210 $ 341,866 $ 38,132 $ 266,104 $ 35,014 Denominator Weighted average shares used in computing net income per share, basic 138,474 14,777 135,547 15,119 130,610 17,186 Net income per share, basic $ 2.79 $ 2.79 $ 2.52 $ 2.52 $ 2.04 $ 2.04 Diluted Numerator Net income, basic $ 386,180 $ 41,210 $ 341,866 $ 38,132 $ 266,104 $ 35,014 Reallocation as a result of conversion of Class B to Class A common stock: Net income, basic 41,210 — 38,132 — 35,014 — Reallocation of net income to Class B common stock — 21,480 — 21,409 — 17,652 Net income, diluted $ 427,390 $ 62,690 $ 379,998 $ 59,541 $ 301,118 $ 52,666 Denominator Number of shares used for basic net income per share computation 138,474 14,777 135,547 15,119 130,610 17,186 Conversion of Class B to Class A common stock 14,777 — 15,119 — 17,186 — Effect of potentially dilutive common shares 9,026 9,026 10,066 10,066 10,500 10,500 Weighted average shares used in computing net income per share, diluted 162,277 23,803 160,732 25,185 158,296 27,686 Net income per share, diluted $ 2.63 $ 2.63 $ 2.36 $ 2.36 $ 1.90 $ 1.90
Potential Common Share Equivalents Excluded where the Inclusion would be Anti-dilutive	Potential common share equivalents excluded where the inclusion would be anti-dilutive are as follows: Fiscal year ended January 31, 2022 2021 2020 Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive 958,476 1,045,222 1,461,255

Revenues by Product (Tables)

Revenues by Product (Tables)	12 Months Ended
	Jan. 31, 2022
Revenue from Contract with Customer [Abstract]
Summary of Total Revenues	Total revenues consist of the following (in thousands): Fiscal year ended January 31, 2022 2021 2020 Subscription services Commercial Solutions $ 876,458 $ 744,856 $ 593,562 R&D Solutions 607,518 434,630 302,732 Total subscription services 1,483,976 1,179,486 896,294 Professional services Commercial Solutions 165,086 142,003 103,825 R&D Solutions 201,715 143,580 103,962 Total professional services 366,801 285,583 207,787 Total revenues $ 1,850,777 $ 1,465,069 $ 1,104,081

Information about Geographic _2

Information about Geographic Areas (Tables)	12 Months Ended
	Jan. 31, 2022
Segment Reporting [Abstract]
Revenues by Geographic Area	Total revenues by geographic area were as follows for the periods shown below (in thousands): Fiscal year ended January 31, 2022 2021 2020 North America $ 1,063,770 $ 838,192 $ 607,704 Europe 509,127 400,790 310,215 Asia Pacific 225,968 183,848 151,052 Middle East, Africa, and Latin America 51,912 42,239 35,110 Total revenues $ 1,850,777 $ 1,465,069 $ 1,104,081
Long-Lived Assets by Geographic Area	Long-lived assets by geographic area are as follows as of the periods shown below (in thousands): January 31, 2022 2021 North America $ 45,625 $ 46,285 Europe 6,135 5,525 Asia Pacific 1,335 1,359 Middle East, Africa, and Latin America 1,400 481 Total long-lived assets $ 54,495 $ 53,650

Summary of Business and Signi_4

Summary of Business and Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Jan. 31, 2022USD ($)segment
Concentration Risk [Line Items]
Number of operating segments | segment	1
Number of reportable segments | segment	1
Highly liquid investments maturity	3 months
Impairment of goodwill | $	$ 0
Impairment recognized for long-lived assets | $	$ 0
Software Development
Concentration Risk [Line Items]
Finite-lived intangible asset, useful life	3 years
Minimum
Concentration Risk [Line Items]
Amortization period of deferred costs	1 year
Customer payment period	30 days
Minimum | 2007 Stock Plan | Restricted Stock Units (RSUs)
Concentration Risk [Line Items]
Share-based compensation cost recognition vesting service period	1 year
Minimum | 2007 Stock Plan | Stock Options
Concentration Risk [Line Items]
Share-based compensation cost recognition vesting service period	4 years
Maximum
Concentration Risk [Line Items]
Amortization period of deferred costs	3 years
Customer payment period	60 days
Maximum | 2007 Stock Plan | Restricted Stock Units (RSUs)
Concentration Risk [Line Items]
Share-based compensation cost recognition vesting service period	5 years
Maximum | 2007 Stock Plan | Stock Options
Concentration Risk [Line Items]
Share-based compensation cost recognition vesting service period	9 years

Summary of Business and Signi_5

Summary of Business and Significant Accounting Policies - Concentrations of Credit Risk (Details) - Accounts Receivable - Customer Concentration Risk	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Customer One
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	12.00%
Customer Two
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%

Summary of Business and Signi_6

Summary of Business and Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Jan. 31, 2022
Building
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	30 years
Land improvements and building improvements
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	10 years
Equipment and computers
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	5 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	Shorter of remaining life of the lease term or estimated useful life

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($) $ in Millions	Nov. 07, 2019	Nov. 01, 2019
Crossix Solutions
Business Acquisition [Line Items]
Percentage of voting interests acquired		100.00%
Consideration transferred		$ 428
Equity retention awards		$ 120
Physicians World
Business Acquisition [Line Items]
Consideration transferred	$ 41
Equity retention awards	$ 15

Acquisitions - Schedule of Asse

Acquisitions - Schedule of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	Nov. 07, 2019	Nov. 01, 2019	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Business Acquisition [Line Items]
Goodwill			$ 439,877	$ 436,029	$ 438,529
Crossix Solutions
Business Acquisition [Line Items]
Net assets acquired		$ 4,766
Total purchased intangible assets		108,500
Goodwill		314,642
Total purchase consideration		427,908
Crossix Solutions | Customer relationships
Business Acquisition [Line Items]
Total purchased intangible assets		$ 70,100
Useful life of intangible assets		10 years
Crossix Solutions | Developed Technology Rights
Business Acquisition [Line Items]
Total purchased intangible assets		$ 19,200
Useful life of intangible assets		6 years
Crossix Solutions | Trade name and trademarks
Business Acquisition [Line Items]
Total purchased intangible assets		$ 13,200
Useful life of intangible assets		5 years
Crossix Solutions | Other intangibles
Business Acquisition [Line Items]
Total purchased intangible assets		$ 6,000
Crossix Solutions | Other intangibles | Minimum
Business Acquisition [Line Items]
Useful life of intangible assets		1 year
Crossix Solutions | Other intangibles | Maximum
Business Acquisition [Line Items]
Useful life of intangible assets		7 years
Physicians World
Business Acquisition [Line Items]
Net assets acquired	$ 1,221
Total purchased intangible assets	11,700
Goodwill	28,083
Total purchase consideration	41,004
Physicians World | Customer relationships
Business Acquisition [Line Items]
Total purchased intangible assets	$ 7,700
Useful life of intangible assets	10 years
Physicians World | Developed Technology Rights
Business Acquisition [Line Items]
Total purchased intangible assets	$ 3,300
Useful life of intangible assets	6 years
Physicians World | Trade name and trademarks
Business Acquisition [Line Items]
Total purchased intangible assets	$ 700
Useful life of intangible assets	5 years

Acquisitions - Schedule of Pro

Acquisitions - Schedule of Pro Forma Information (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2021USD ($)$ / shares
Business Combination and Asset Acquisition [Abstract]
Pro forma revenues | $	$ 1,153,497
Pro forma net income | $	$ 278,215
Pro forma net income per share:
Basic (in dollars per share) | $ / shares	$ 1.88
Diluted (in dollars per share) | $ / shares	$ 1.76

Short-Term Investments - Schedu

Short-Term Investments - Schedule of Short-Term Investments (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 1,247,165	$ 929,273
Gross unrealized gains	392	3,879
Gross unrealized losses	(9,493)	(30)
Estimated fair value	1,238,064	933,122
Certificates of deposits
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	13,500	17,350
Gross unrealized gains	0	15
Gross unrealized losses	(15)	(1)
Estimated fair value	13,485	17,364
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	191,676	125,833
Gross unrealized gains	45	745
Gross unrealized losses	(1,432)	(2)
Estimated fair value	190,289	126,576
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	29,432	57,390
Gross unrealized gains	0	8
Gross unrealized losses	(2)	(2)
Estimated fair value	29,430	57,396
Corporate notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	669,489	428,710
Gross unrealized gains	276	2,360
Gross unrealized losses	(5,856)	(23)
Estimated fair value	663,909	431,047
Foreign government bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	24,577	31,855
Gross unrealized gains	13	45
Gross unrealized losses	(179)	(2)
Estimated fair value	24,411	31,898
U.S. agency obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	27,978	52,756
Gross unrealized gains	12	119
Gross unrealized losses	(254)	0
Estimated fair value	27,736	52,875
U.S. treasury securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	290,513	215,379
Gross unrealized gains	46	587
Gross unrealized losses	(1,755)	0
Estimated fair value	$ 288,804	$ 215,966

Short-Term Investments - Summar

Short-Term Investments - Summary of Estimated Fair Value of Short-Term Investments, Designated as Available-for-Sale and Classified by Contractual Maturity (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Due in one year or less	$ 457,948	$ 428,155
Due in greater than one year	780,116	504,967
Total short-term investments	$ 1,238,064	$ 933,122

Short-Term Investments - Sche_2

Short-Term Investments - Schedule of Fair Values and Gross Unrealized Loss Position of Available-for-Sale Securities Aggregated by Investment Category (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Certificates of deposits
Schedule of Available-for-sale Securities [Line Items]
Fair value	$ 5,985	$ 3,749
Gross unrealized losses	(15)	(2)
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Fair value	177,056	3,318
Gross unrealized losses	(1,432)	(1)
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Fair value	17,190	17,626
Gross unrealized losses	(2)	(2)
Corporate notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Fair value	571,099	29,558
Gross unrealized losses	(5,856)	(23)
Foreign government bonds
Schedule of Available-for-sale Securities [Line Items]
Fair value	19,594	2,679
Gross unrealized losses	(179)	$ (2)
U.S. agency obligations
Schedule of Available-for-sale Securities [Line Items]
Fair value	24,725
Gross unrealized losses	(254)
U.S. treasury securities
Schedule of Available-for-sale Securities [Line Items]
Fair value	247,509
Gross unrealized losses	$ (1,756)

Deferred Costs (Details)

Deferred Costs (Details) - USD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Deferred Costs [Abstract]
Deferred costs	$ 33,106,000	$ 42,072,000
Amortization of deferred costs	26,000,000	21,000,000	$ 21,000,000
Impairment losses recorded in relation to the costs capitalized	$ 0	$ 0	$ 0

Property and Equipment, Net - C

Property and Equipment, Net - Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 84,769	$ 83,266
Less accumulated depreciation	(30,274)	(29,616)
Total property and equipment, net	54,495	53,650
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,040	3,040
Building
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,984	20,984
Land improvements and building improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,392	22,392
Equipment and computers
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,581	8,847
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	15,040	13,452
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,002	13,945
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 730	$ 606

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 7	$ 9	$ 9

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Goodwill	$ 439,877	$ 436,029	$ 438,529
Amortization expense	$ 19,000	$ 20,000	$ 10,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 436,029	$ 438,529
Purchase price goodwill reduction from Crossix tax adjustments		(2,500)
Goodwill from business acquisitions	3,848
Goodwill, ending balance	$ 439,877	$ 436,029

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Details of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 177,042	$ 171,176
Accumulated amortization	(75,102)	(56,581)
Net	101,940	114,595
Existing technology
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	28,580	26,180
Accumulated amortization	(12,187)	(8,367)
Net	$ 16,393	$ 17,813
Remaining useful life (in years)	3 years 10 months 24 days	4 years 9 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 113,157	$ 110,643
Accumulated amortization	(38,829)	(27,741)
Net	$ 74,328	$ 82,902
Remaining useful life (in years)	7 years	8 years
Trade name and trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 13,900	$ 13,900
Accumulated amortization	(6,645)	(4,005)
Net	$ 7,255	$ 9,895
Remaining useful life (in years)	2 years 9 months 18 days	3 years 9 months 18 days
Other intangibles
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 21,405	$ 20,453
Accumulated amortization	(17,441)	(16,468)
Net	$ 3,964	$ 3,985
Remaining useful life (in years)	3 years 9 months 18 days	5 years 1 month 6 days

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Estimated Amortization Expense (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Fiscal 2023	$ 19,463
Fiscal 2024	19,459
Fiscal 2025	18,557
Fiscal 2026	14,147
Fiscal 2027	8,922
Thereafter	21,392
Net	$ 101,940	$ 114,595

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Payables and Accruals [Abstract]
Accrued commissions	$ 8,556	$ 7,498
Accrued bonus	4,677	4,134
Accrued vacation	5,546	4,716
Payroll tax payable	9,487	10,250
Accrued other compensation and benefits	5,568	3,812
Total accrued compensation and benefits	33,834	30,410
Accrued fees payable to salesforce.com	6,521	6,381
Taxes payable	9,743	13,598
Accrued third-party professional services subcontractors' fees	1,961	1,515
Other accrued expenses	17,884	9,488
Total accrued expenses and other current liabilities	$ 36,109	$ 30,982

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Assets
Short-term investments	$ 1,238,064	$ 933,122
U.S. treasury securities
Assets
Short-term investments	288,804	215,966
Certificates of deposits
Assets
Short-term investments	13,485	17,364
Asset-backed securities
Assets
Short-term investments	190,289	126,576
Commercial paper
Assets
Short-term investments	29,430	57,396
Corporate notes and bonds
Assets
Short-term investments	663,909	431,047
Foreign government bonds
Assets
Short-term investments	24,411	31,898
U.S. agency obligations
Assets
Short-term investments	27,736	52,875
Fair value, measurements recurring
Assets
Total financial assets	1,676,118	1,209,019
Liabilities
Total financial liabilities		72
Fair value, measurements recurring | Money market funds
Assets
Cash equivalents:	428,411	259,937
Fair value, measurements recurring | U.S. treasury securities
Assets
Cash equivalents:		15,520
Short-term investments	288,804	215,966
Fair value, measurements recurring | Certificates of deposits
Assets
Short-term investments	13,485	17,364
Fair value, measurements recurring | Asset-backed securities
Assets
Cash equivalents:	2,568
Short-term investments	190,289	126,576
Fair value, measurements recurring | Commercial paper
Assets
Short-term investments	29,430	57,396
Fair value, measurements recurring | Corporate notes and bonds
Assets
Cash equivalents:	5,853
Short-term investments	663,909	431,047
Fair value, measurements recurring | Foreign government bonds
Assets
Short-term investments	24,411	31,898
Fair value, measurements recurring | U.S. agency obligations
Assets
Short-term investments	27,736	52,875
Fair value, measurements recurring | Foreign currency derivative contracts
Assets
Short-term investments	1,222	440
Fair value, measurements recurring | Foreign currency derivative contracts
Liabilities
Foreign currency derivative contracts		72
Fair value, measurements recurring | Level 1
Assets
Total financial assets	428,411	259,937
Liabilities
Total financial liabilities		0
Fair value, measurements recurring | Level 1 | Money market funds
Assets
Cash equivalents:	428,411	259,937
Fair value, measurements recurring | Level 1 | U.S. treasury securities
Assets
Cash equivalents:		0
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Certificates of deposits
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Asset-backed securities
Assets
Cash equivalents:	0
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Commercial paper
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Corporate notes and bonds
Assets
Cash equivalents:	0
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Foreign government bonds
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | U.S. agency obligations
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Foreign currency derivative contracts
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Foreign currency derivative contracts
Liabilities
Foreign currency derivative contracts		0
Fair value, measurements recurring | Level 2
Assets
Total financial assets	1,247,707	949,082
Liabilities
Total financial liabilities		72
Fair value, measurements recurring | Level 2 | Money market funds
Assets
Cash equivalents:	0	0
Fair value, measurements recurring | Level 2 | U.S. treasury securities
Assets
Cash equivalents:		15,520
Short-term investments	288,804	215,966
Fair value, measurements recurring | Level 2 | Certificates of deposits
Assets
Short-term investments	13,485	17,364
Fair value, measurements recurring | Level 2 | Asset-backed securities
Assets
Cash equivalents:	2,568
Short-term investments	190,289	126,576
Fair value, measurements recurring | Level 2 | Commercial paper
Assets
Short-term investments	29,430	57,396
Fair value, measurements recurring | Level 2 | Corporate notes and bonds
Assets
Cash equivalents:	5,853
Short-term investments	663,909	431,047
Fair value, measurements recurring | Level 2 | Foreign government bonds
Assets
Short-term investments	24,411	31,898
Fair value, measurements recurring | Level 2 | U.S. agency obligations
Assets
Short-term investments	27,736	52,875
Fair value, measurements recurring | Level 2 | Foreign currency derivative contracts
Assets
Short-term investments	$ 1,222	440
Fair value, measurements recurring | Level 2 | Foreign currency derivative contracts
Liabilities
Foreign currency derivative contracts		$ 72

Fair Value Measurements - Summa

Fair Value Measurements - Summary Fair Value of Outstanding Derivative Instruments (Details) - Foreign currency derivative contracts - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Derivatives, Fair Value [Line Items]
Notional amount of foreign currency derivative contracts	$ 87,097	$ 52,516
Fair value of foreign currency derivative contracts	$ 85,876	$ 52,148

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Outstanding Balance Sheet Hedges (Details) - Foreign currency derivative contracts - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Foreign currency derivative contracts - assets	$ 1,222	$ 440
Accrued expenses
Derivatives, Fair Value [Line Items]
Foreign currency derivative contracts - liabilities	$ 0	$ 72

Income Taxes - Components of In

Income Taxes - Components of Income before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Income Tax Disclosure [Abstract]
United States	$ 487,962	$ 378,042	$ 305,339
Foreign	24,349	15,951	8,358
Income before income taxes	$ 512,311	$ 393,993	$ 313,697

Income Taxes - Components of Pr

Income Taxes - Components of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Current provision:
Federal	$ 53,426	$ 7,108	$ 11,143
State	12,580	4,763	4,695
Foreign	7,837	2,825	3,404
Total current provision	73,843	14,696	19,242
Deferred provision:
Federal	1,870	(816)	(1,063)
State	945	681	(517)
Foreign	8,264	(566)	(5,083)
Total deferred provision	11,079	(701)	(6,663)
Provision for income taxes	$ 84,921	$ 13,995	$ 12,579

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2019
Income Tax Contingency [Line Items]
Federal statutory income tax rate	21.00%	21.00%	21.00%
Federal net operating loss carryforwards	$ 48,000
State net operating loss carryforwards	69,000
Foreign net operating loss carryforwards	31,000
Unrecognized tax benefits	25,241	$ 18,628	$ 14,515	$ 12,597
Unrecognized tax benefits that would impact effective tax rate	14,000
State and Local Jurisdiction | California Franchise Tax Board
Income Tax Contingency [Line Items]
Tax credit carryforward	$ 54,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Federal Income Tax to Effective Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Income Tax Disclosure [Abstract]
Federal tax statutory tax rate	$ 107,585	$ 82,739	$ 65,876
State taxes	11,035	4,401	3,035
Tax credits	(25,968)	(24,617)	(23,468)
Stock-based compensation	(29,715)	(54,488)	(34,569)
Valuation allowance	19,402	10,269	7,408
Foreign derived intangible income deduction (FDII)	(3,406)	(5,134)	(4,836)
Other	5,988	825	(867)
Provision for income taxes	$ 84,921	$ 13,995	$ 12,579

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Deferred tax assets:
Accruals and reserves	$ 7,068	$ 13,494
Capitalized expenditures	10,477	0
Stock-based compensation	16,615	11,486
Net operating loss carryforward	21,850	29,318
Tax credit carryforward	34,725	29,624
Lease liabilities	13,813	15,932
Other	2,955	977
Gross deferred tax assets	107,503	100,831
Valuation allowance	(48,484)	(31,318)
Total deferred tax assets	59,019	69,513
Deferred tax liabilities:
Intangible assets	(31,200)	(30,253)
Lease right-of-use assets	(12,497)	(14,438)
Deferred costs	(10,552)	(11,481)
Other	(1,889)	(1,076)
Total deferred tax liabilities	(56,138)	(57,248)
Net deferred tax assets	$ 2,881	$ 12,265

Income Taxes - Summary of Chang

Income Taxes - Summary of Changes in Total Gross Amount of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance	$ 18,628	$ 14,515	$ 12,597
Increases related to tax positions taken during the prior period	3,218	96	796
Increases related to tax positions taken during the current period	4,122	4,126	3,420
Decreases related to tax positions taken during the prior period	0	(51)	(128)
Audit settlements	(195)	0	0
Lapse of statute of limitations	(532)	(58)	(2,170)
Ending balance	$ 25,241	$ 18,628	$ 14,515

Deferred Revenue, Performance_2

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Revenue From Contracts With Customers [Line Items]
Unbilled accounts receivable	$ 63,266	$ 47,206
Subscription services
Revenue From Contracts With Customers [Line Items]
Recognition of deferred revenue	605,000	464,000	$ 353,000
Revenue expected to be recognized from remaining performance obligations	1,507,000
Unbilled accounts receivable	36,000	27,000
Professional services and other
Revenue From Contracts With Customers [Line Items]
Unbilled accounts receivable	$ 28,000	$ 20,000

Deferred Revenue, Performance_3

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable - Performance Obligation Duration (Details) - Subscription services - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01	Jan. 31, 2022
Revenue From Contracts With Customers [Line Items]
Revenue, remaining performance obligation, percentage	79.00%
Revenue, remaining performance obligation, recognition period	12 months

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Leases [Line Items]
Operating lease expense	$ 14	$ 13	$ 8
Maximum
Leases [Line Items]
Operating leases, options to extend leases term	9 years
Finance leases, options to extend leases term	9 years

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 13,800	$ 11,401
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 3,848	$ 12,214

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Leases [Abstract]
Lease right-of-use assets	$ 49,640	$ 56,917
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Lease liabilities	Lease liabilities
Lease liabilities	$ 10,981	$ 11,347
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Lease liabilities, noncurrent	Lease liabilities, noncurrent
Lease liabilities, noncurrent	$ 43,607	$ 51,393
Total operating lease liabilities	$ 54,588	$ 62,740
Weighted Average Remaining Lease Term	6 years	6 years 8 months 12 days
Weighted Average Discount Rate	3.70%	3.80%

Leases- Maturities of Lease Lia

Leases- Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Fiscal 2023	$ 12,143
Fiscal 2024	11,942
Fiscal 2025	8,951
Fiscal 2026	7,251
Fiscal 2027	6,316
Thereafter	14,674
Total operating lease payments	61,277
Less imputed interest	6,689
Total operating lease liabilities	$ 54,588	$ 62,740

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)	12 Months Ended
	Jan. 31, 2022USD ($)vote$ / sharesshares	Jan. 31, 2021$ / sharesshares	Jan. 31, 2020$ / shares	Jan. 29, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends payable | $	$ 0
Options outstanding (in shares)	12,090,522	12,761,289
Unrecognized compensation cost related to unvested stock options granted | $	$ 229,000,000
Share price (in usd per share) | $ / shares				$ 236.54
Intrinsic value of options exercised | $	$ 363,000,000
Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued (in shares)	139,432,822	137,062,817
Common stock, shares outstanding (in shares)	139,432,822	137,062,817
Vote per common share | vote	1
Class B common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued (in shares)	14,763,775	14,993,991
Common stock, shares outstanding (in shares)	14,763,775	14,993,991
Vote per common share | vote	10
2007 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	0
2021 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	0
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	0
Number of additional shares authorized (in shares)	13,750,000
Common stock, shares outstanding, percentage	5.00%
Weighted-average grant date fair value of options granted (in usd per share) | $ / shares	$ 108.42	$ 71.86	$ 60.05
2013 Equity Incentive Plan | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued in period (in shares)	6,082,272
2013 Equity Incentive Plan | Class A common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)	38,720,277
2013 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)	2,200,000
Common stock, shares outstanding, percentage	1.00%
Number of shares reserved for future issuance (in shares)	4,000,000
Number of shares authorized (in shares)	4,897,856
Percent of fair market value paid for shares	85.00%
Percentage of payroll deductions for shares acquired	15.00%
2013 Employee Stock Purchase Plan | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued in period (in shares)	0
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Weighted average period of unvested stock (in years)	1 year 2 months 12 days
Unrecognized compensation cost related to unvested RSUs | $	$ 90,000,000
Total intrinsic value, vested | $	$ 246,000,000
Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Restricted Stock Units (RSUs) | 2007 Stock Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation cost recognition vesting service period	1 year
Restricted Stock Units (RSUs) | 2007 Stock Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation cost recognition vesting service period	5 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Weighted average period of unvested stock (in years)	2 years 7 months 6 days
Stock Options | 2007 Stock Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Share-based compensation cost recognition vesting service period	4 years
Stock Options | 2007 Stock Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	5 years
Options exercisable period	10 years
Share-based compensation cost recognition vesting service period	9 years
Stock Options | 2013 Equity Incentive Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	5 years
Stock Options | 2013 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	9 years
Options exercisable period	10 years

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Number of shares
Options outstanding, beginning balance (in shares)	12,761,289
Options granted (in shares)	1,155,396
Options exercised (in shares)	(1,476,898)
Options forfeited/cancelled (in shares)	(349,265)
Options outstanding, ending balance (in shares)	12,090,522	12,761,289
Options vested and exercisable (in shares)	7,203,834
Options vested and exercisable and expected to vest thereafter (in shares)	12,090,522
Weighted average exercise price
Options outstanding, beginning balance (in usd per share)	$ 57.48
Options granted (in usd per share)	277.06
Options exercised (in usd per share)	34.90
Options forfeited/cancelled (in usd per share)	172.64
Options outstanding, ending balance (in usd per share)	77.89	$ 57.48
Options vested and exercisable (in usd per share)	32.35
Options vested and exercisable and expected to vest thereafter (in usd per share)	$ 77.89
Weighted average remaining contractual term (in years), options outstanding	4 years 7 months 6 days	5 years
Weighted average remaining contractual term (in years), options vested and exercisable	2 years 9 months 18 days
Weighted average remaining contractual term (in years), options vested and exercisable and expected to vest thereafter	4 years 7 months 6 days
Aggregate intrinsic value (in millions)
Options outstanding	$ 1,964	$ 2,794
Options vested and exercisable	1,472
Options vested and exercisable and expected to vest thereafter	$ 1,964

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Weighted-Average Assumptions Used to Estimate Grant Date Fair Value of Options Granted (Details) - Stock Options	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	0.70%	0.33%	1.39%
Risk-free interest rate, maximum	1.60%	1.43%	2.52%
Dividend yield	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	37.00%	39.00%	39.00%
Expected term (in years)	6 years 3 months	6 years 3 months	5 years 7 months 20 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	39.00%	42.00%	41.00%
Expected term (in years)		7 years 3 months	6 years 7 months 9 days

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Restricted Stock Unit (RSU) Activity (Details) - Restricted Stock Units (RSUs)	12 Months Ended
	Jan. 31, 2022$ / sharesshares
Unreleased restricted stock units
Beginning balance (in shares) | shares	1,032,215
RSUs granted (in shares) | shares	518,172
RSUs vested (in shares) | shares	(854,536)
RSUs forfeited/cancelled (in shares) | shares	(76,463)
Ending balance (in shares) | shares	619,388
Weighted  average grant date fair value
Beginning balance (in usd per share) | $ / shares	$ 121.98
RSUs granted (in usd per share) | $ / shares	277.79
RSUs vested (in usd per share) | $ / shares	173.01
RSUs forfeited/cancelled (in usd per share) | $ / shares	175.88
Ending balance (in usd per share) | $ / shares	$ 175.23

Other Income (Details)

Other Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Other Income and Expenses [Abstract]
Foreign currency (loss) gain	$ (714)	$ 2,275	$ (708)
(Amortization) accretion on investments	(7,201)	(3,082)	3,001
Interest income, net	14,730	15,859	25,185
Miscellaneous income	0	1,147	0
Other income, net	$ 6,815	$ 16,199	$ 27,478

Net Income per Share - Numerato

Net Income per Share - Numerators and Denominators of the Basic and Diluted EPS Computations for Common Stock (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Weighted average shares used in computing net income per share, basic (in shares)	153,251	150,666	147,796
Net income per share, basic (in usd per share)	$ 2.79	$ 2.52	$ 2.04
Reallocation as a result of conversion of Class B to Class A common stock:
Weighted average shares used in computing net income per share, diluted (in shares)	162,277	160,732	158,296
Net income per share, diluted (in usd per share)	$ 2.63	$ 2.36	$ 1.90
Class A common stock
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income, basic	$ 386,180	$ 341,866	$ 266,104
Weighted average shares used in computing net income per share, basic (in shares)	138,474	135,547	130,610
Net income per share, basic (in usd per share)	$ 2.79	$ 2.52	$ 2.04
Net income, basic	$ 386,180	$ 341,866	$ 266,104
Reallocation as a result of conversion of Class B to Class A common stock:
Net income, basic	41,210	38,132	35,014
Reallocation of net income to Class B common stock	0	0	0
Net income, diluted	$ 427,390	$ 379,998	$ 301,118
Conversion of Class B to Class A common stock (in shares)	14,777	15,119	17,186
Effect of potentially dilutive common shares (in shares)	9,026	10,066	10,500
Weighted average shares used in computing net income per share, diluted (in shares)	162,277	160,732	158,296
Net income per share, diluted (in usd per share)	$ 2.63	$ 2.36	$ 1.90
Class B common stock
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income, basic	$ 41,210	$ 38,132	$ 35,014
Weighted average shares used in computing net income per share, basic (in shares)	14,777	15,119	17,186
Net income per share, basic (in usd per share)	$ 2.79	$ 2.52	$ 2.04
Net income, basic	$ 41,210	$ 38,132	$ 35,014
Reallocation as a result of conversion of Class B to Class A common stock:
Net income, basic	0	0	0
Reallocation of net income to Class B common stock	21,480	21,409	17,652
Net income, diluted	$ 62,690	$ 59,541	$ 52,666
Conversion of Class B to Class A common stock (in shares)	0	0	0
Effect of potentially dilutive common shares (in shares)	9,026	10,066	10,500
Weighted average shares used in computing net income per share, diluted (in shares)	23,803	25,185	27,686
Net income per share, diluted (in usd per share)	$ 2.63	$ 2.36	$ 1.90

Net Income per Share - Potentia

Net Income per Share - Potential Common Share Equivalents Excluded where the Inclusion would be Anti-dilutive (Details) - shares	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Earnings Per Share [Abstract]
Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive (in shares)	958,476	1,045,222	1,461,255

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 13, 2017USD ($)	Jan. 26, 2017employee	Mar. 22, 2022antitrust_claim
IQVIA Litigation Matter | Subsequent Event
Long-term Purchase Commitment [Line Items]
Pending antitrust claims against Veeva			4
Number of pending claims			5
IQVIA Litigation Matter | Minimum
Long-term Purchase Commitment [Line Items]
Monetary damages | $	$ 200
Medidata Litigation Matter
Long-term Purchase Commitment [Line Items]
Number of former employees | employee		5

Revenues by Product - Summary o

Revenues by Product - Summary of Total Revenues (Details) $ in Thousands	12 Months Ended
	Jan. 31, 2022USD ($)	Jan. 31, 2021USD ($)	Jan. 31, 2020USD ($)	Jul. 31, 2021industry
Disaggregation of Revenue [Line Items]
Number of product areas | industry				2
Total revenues	$ 1,850,777	$ 1,465,069	$ 1,104,081
Total subscription services
Disaggregation of Revenue [Line Items]
Total revenues	1,483,976	1,179,486	896,294
Commercial Solutions
Disaggregation of Revenue [Line Items]
Total revenues	876,458	744,856	593,562
R&D Solutions
Disaggregation of Revenue [Line Items]
Total revenues	607,518	434,630	302,732
Total professional services
Disaggregation of Revenue [Line Items]
Total revenues	366,801	285,583	207,787
Commercial Solutions
Disaggregation of Revenue [Line Items]
Total revenues	165,086	142,003	103,825
R&D Solutions
Disaggregation of Revenue [Line Items]
Total revenues	$ 201,715	$ 143,580	$ 103,962

Information about Geographic _3

Information about Geographic Areas - Revenues by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Revenues by geography
Total revenues	$ 1,850,777	$ 1,465,069	$ 1,104,081
North America
Revenues by geography
Total revenues	1,063,770	838,192	607,704
Europe
Revenues by geography
Total revenues	509,127	400,790	310,215
Asia Pacific
Revenues by geography
Total revenues	225,968	183,848	151,052
Middle East, Africa, and Latin America
Revenues by geography
Total revenues	$ 51,912	$ 42,239	$ 35,110

Information about Geographic _4

Information about Geographic Areas - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Jan. 31, 2022	Jan. 31, 2021
Long-lived assets by geography
Total long-lived assets	$ 54,495	$ 53,650
North America
Long-lived assets by geography
Total long-lived assets	45,625	46,285
Europe
Long-lived assets by geography
Total long-lived assets	6,135	5,525
Asia Pacific
Long-lived assets by geography
Total long-lived assets	1,335	1,359
Middle East, Africa, and Latin America
Long-lived assets by geography
Total long-lived assets	$ 1,400	$ 481

401(k) Plan (Details)

401(k) Plan (Details) - USD ($)	12 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Defined Contribution Plan Disclosure [Line Items]
Total expense related defined benefit plan	$ 7,000,000	$ 6,000,000	$ 4,000,000
401(k) plan
Defined Contribution Plan Disclosure [Line Items]
Employer maximum matching contribution amount per employee per year	2,000
RRSP | CANADA
Defined Contribution Plan Disclosure [Line Items]
Employer maximum matching contribution amount per employee per year	$ 2,000

Uncategorized Items - veev-2022

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-02 [Member]